Patent Grant
10779971
This invention relates to treatment of atherosclerotic occlusive disease by intravascular procedures for pushing and holding plaque accumulated on the blood vessel walls out of the way for reopened blood flow.
Atherosclerotic occlusive disease is the primary cause of stroke, heart attack, limb loss, and death in the US and the industrialized world. Atherosclerotic plaque forms a hard layer along the wall of an artery and is comprised of calcium, cholesterol, compacted thrombus and cellular debris. As the atherosclerotic disease progresses, the blood supply intended to pass through a specific blood vessel is diminished or even prevented by the occlusive process. One of the most widely utilized methods of treating clinically significant atherosclerotic plaque is balloon angioplasty.
Balloon angioplasty is an accepted method of opening blocked or narrowed blood vessels in every vascular bed in the body. Balloon angioplasty is performed with a balloon angioplasty catheter. The balloon angioplasty catheter consists of a cigar shaped, cylindrical balloon attached to a catheter. The balloon angioplasty catheter is placed into the artery from a remote access site that is created either percutaneously or through open exposure of the artery. The catheter is passed along the inside of the blood vessel over a wire that guides the way of the catheter. The portion of the catheter with the balloon attached is placed at the location of the atherosclerotic plaque that requires treatment. The balloon is inflated to a size that is consistent with the original diameter of the artery prior to developing occlusive disease. When the balloon is inflated, the plaque is broken. Cleavage planes form within the plaque, permitting the plaque to expand in diameter with the expanding balloon. Frequently, a segment of the plaque is more resistant to dilatation than the remainder of the plaque. When this occurs, greater pressure pumped into the balloon results in full dilatation of the balloon to its intended size. The balloon is deflated and removed and the artery segment is reexamined. The process of balloon angioplasty is one of uncontrolled plaque disruption. The lumen of the blood vessel at the site of treatment is usually somewhat larger, but not always and not reliably.
Some of the cleavage planes created by fracture of the plaque with balloon angioplasty can form a dissection. A dissection occurs when a portion of the plaque is lifted away from the artery, is not fully adherent to the artery and may be mobile or loose. The plaque that has been disrupted by dissection protrudes into the flow stream. If the plaque lifts completely in the direction of blood flow, it may impede flow or cause acute occlusion of the blood vessel. There is evidence that dissection after balloon angioplasty must be treated to prevent occlusion and to resolve residual stenosis. There is also evidence that in some circumstances, it is better to place a metal retaining structure, such as stent to hold open the artery after angioplasty and force the dissected material back against the wall of the blood vessel to create an adequate lumen for blood flow.
The clinical management of dissection after balloon angioplasty is currently performed primarily with stents. As illustrated in
However, stents have significant disadvantages and much research and development is being done to address these issues. Stents induce repeat narrowing of the treated blood vessel (recurrent stenosis). Recurrent stenosis is the “Achilles heel” of stenting. Depending on the location and the size of the artery, in-growth of intimal hyperplastic tissue from the vessel wall in between struts or through openings in the stent may occur and cause failure of the vascular reconstruction by narrowing or occlusion of the stent. This may occur any time after stent placement. In many cases, the stent itself seems to incite local vessel wall reaction that causes stenosis, even in the segment of the stent that was placed over artery segments that were not particularly narrowed or diseased during the original stent procedure. This reaction of the blood vessel to the presence of the stent is likely due to the scaffolding effect of the stent. This reaction of recurrent stenosis or tissue in growth of the blood vessel is in response to the stent. This activity shows that the extensive use of metal and vessel coverage in the artery as happens with stenting is contributing to the narrowing. The recurrent stenosis is a problem because it causes failure of the stent and there is no effective treatment. Existing treatment methods that have been used for this problem include; repeat angioplasty, cutting balloon angioplasty, cryoplasty, atherectomy, and even repeat stenting. None of these methods have a high degree of long-term success.
Stents may also fracture due to material stress. Stent fracture may occur with chronic material stress and is associated with the development of recurrent stenosis at the site of stent fracture. This is a relatively new finding and it may require specialized stent designs for each application in each vascular bed. Structural integrity of stents remains a current issue for their use. Arteries that are particularly mobile, such as the lower extremity arteries and the carotid arteries, are of particular concern. The integrity of the entire stent is tested any time the vessel bends or is compressed anywhere along the stented segment. One reason why stent fractures may occur is because a longer segment of the artery has been treated than is necessary. The scaffolding effect of the stent affects the overall mechanical behavior of the artery, making the artery less flexible. Available stenting materials have limited bending cycles and are prone to failure at repeated high frequency bending sites.
Many artery segments are stented even when they do not require it, thereby exacerbating the disadvantages of stents. There are several reasons for this. Many cases require more than one stent to be placed and often several are needed. Much of the stent length is often placed over artery segments that do not need stenting and are merely adjoining an area of dissection or disease. Stents that are adjusted to the precise length of the lesion are not available. When one attempts to place multiple stents and in the segments most in need of stenting, the cost is prohibitive since installation and material is required per stent. The time it takes to do this also adds to the cost and risk of the procedure. The more length of artery that receives a stent that it does not need, the more stiffness is conferred to the artery, and the more scaffolding affect occurs. This may also help to incite the arterial reaction to the stent that causes recurrent stenosis.
There exists a continuing need to develop new and improved devices to assist in the treatment of vascular disease, including atherosclerotic occlusive disease, among other conditions, and such as for the purposes outlined above. Some embodiments of an endoluminal staple or tack device can include one or more of the following features: a single column cell design, controlled angle of struts, tapered struts, struts having more than one sinusoidal pattern amplitude, a row of anchors, anchors in the middle of the device, flat midline markers, simultaneous device placement, and a force curve with a slope of about −0.3 N/mm or less. In certain embodiments, an endoluminal staple is provided with a force curve having a slope within a range of about −0.1 to about −0.3 N/mm. In other embodiment, an endoluminal staple is provided with a force curve having a slope within a range of about −0.06 to about −0.1 N/mm. In other embodiment, an endoluminal staple is provided with a force curve having a slope within a range of about −0.006 to about −0.06 N/mm.
Some embodiments of a catheter based endoluminal staple device, or plaque tack, can have a single column cell design.
A catheter based endoluminal staple can include proximal and distal circumferential members. The proximal circumferential member can be disposed at a proximal end of the endoluminal staple. The distal circumferential member can be disposed at a distal end of the endoluminal staple. In some embodiments, the distal circumferential member is the distal most aspect of the endoluminal staple and the proximal circumferential member is the proximal most aspect of the endoluminal staple. The proximal and distal circumferential members can be connected by bridge members. The bridge members can divide an outer surface of the endoluminal staple into cells bounded by the bridge members and a portion of each of the proximal and distal circumferential members.
A catheter based endoluminal staple can include proximal and distal circumferential members. The proximal circumferential member can be disposed at a proximal end of the endoluminal staple, the proximal circumferential member having a sinusoidal configuration. The distal circumferential member can be disposed at a distal end of the endoluminal staple, the distal circumferential member having a sinusoidal configuration. In some embodiments, the distal circumferential member is the distal most aspect of the endoluminal staple and the proximal circumferential member is the proximal most aspect of the endoluminal staple.
In some embodiments, the endoluminal staple can include a first plurality of distally extending apices having a first amplitude and a second plurality of distally extending apices having a second amplitude greater than the first amplitude. It may also, or alternatively, have a first plurality of proximally extending apices having a first amplitude and a second plurality of proximally extending apices having a second amplitude greater than the first amplitude.
In some embodiments, the endoluminal staple can include a bridge member connecting each apex of the second plurality of apices of the proximal circumferential member to each apex of the second plurality of apices of the distal circumferential member. In addition, or alternatively, at an axially aligned position, each apex of the first plurality of apices of the proximal circumferential member can be unconnected to each apex of the first plurality of apices of the distal circumferential member at a corresponding circumferential position.
In certain embodiments, a staple is configured with a plurality of struts on a circumferential member and one or more angles between the struts is controlled. In particular, the angles of the outward apexes of the circumferential member can be controlled. By controlling these angles in particular, production run quality can be improved and the staple is better able to distribute stresses evenly along the circumferential member.
In other embodiments, an endoluminal staple is provided that includes a plurality of circumferential members, at least one of which comprises a plurality of struts. The struts can be configured with a taper along their length, to control the manner in which the struts are loaded. The taper can be the same or different along each strut or along each type of strut. For example, each circumferential member can be made up of a pattern of repeating struts, with each type of strut having a particular taper. In some embodiments, the struts can alternate from a wider end to a shorter end and then the next strut can have a shorter end followed by a wider end. Other configurations are also possible, increasingly wider struts being just one additional example.
As another example, a circumferential member with a plurality of struts can be on a distal end of an endoluminal staple. A first strut can be tapered such that a proximal portion of the strut is narrower than a distal portion of the strut. A second strut is connected to the first strut at distal ends of the first and second struts. The second strut can have the same or a different taper. For example, the second strut can also have a proximal portion narrower than a distal portion of the second strut, while also being narrower overall than the first strut. A third strut can be connected to the second strut at proximal ends of the second and third struts. The third strut can have a proximal portion of the strut that is wider than a distal portion of the strut. A fourth strut can be connected to the third strut at distal ends of the third and fourth struts. The fourth strut can have a proximal portion of the strut that is wider than a distal portion of the strut. The fourth strut can have the same or a different taper from the third strut. For example, the fourth strut can wider overall than the third strut.
In certain embodiments, an endoluminal staple has a first circumferential member disposed at a distal end of the endoluminal staple, the first circumferential member comprising a repeating pattern of first and second outward apices spaced apart by first and second inward apices. The amplitude of the second outward apices can be less than the amplitude of the first apices. The endoluminal staple can also have a second circumferential member disposed at a proximal end. The second circumferential member can be a mirror image of the first circumferential member.
In certain embodiments, an endoluminal staple has a first circumferential member disposed at a distal end of the endoluminal staple and a second circumferential member disposed at a proximal end. The second circumferential member can be a mirror image of the first circumferential member. The first and second circumferential members can be connected by a plurality of bridge members. In some embodiments, the bridge members can include one or more anchors configured to engage the plaque and/or the blood vessel wall.
In certain embodiments, an endoluminal staple can be configured for simultaneous deployment wherein the entire staple is released from the delivery catheter prior to the staple contacting the blood vessel lumen where it is to be placed. Simultaneous deployment is most likely in larger vessels, for example, vessels larger than (e.g., having a diameter that is larger than) 80% of the length of the staple will generally permit simultaneous deployment. For one embodiment of the endoluminal staple, such vessels include superficial femoral artery, iliac, popliteal, and tibial.
In certain embodiments, an endoluminal staple is provided with features that allow the staple to remain in a delivery catheter after a delivery sheath has been withdrawn releasing at least part of, or an entire circumferential member. The circumferential member can make up almost one half of an axial length of the staple. The staple can also be configured for simultaneous deployment when released.
In certain embodiments, an endoluminal staple can have a force curve with an extended area having a low slope. A force curve plots the amount of expansive force exerted, e.g., radially outwardly directed, by a self expanding staple or stent when moving from a compressed state to an expanded state. In some embodiments, the low slope of the force curve can be over a 2.5 mm outer diameter expansion range with a change in force of less than 1 N. In some embodiments, the slope can be less than −0.3 N/mm.
A tack device can be used in a method to treat any plaque dissection in the blood vessel after balloon angioplasty by installing the tack with an expansion force against the plaque to hold it against the blood vessel walls. One method encompasses one wherein balloon angioplasty is first performed, and if there is any damage, disruption, dissection, or irregularity to the blood vessel caused by the balloon angioplasty mechanism, one or more tack devices may be used to tack down the damaged, disrupted, dissected, or irregular blood vessel surface, so as to avoid the need to install a stent and thereby maintain a “stent-free” environment.
These and other features, aspects and advantages are described below with reference to drawings of preferred embodiments, which are intended to illustrate but not to limit the present invention.
The subject matter of this application is directed to the improvement of a plaque tack or staple device. The plaque tack or staple device can be used for treating atherosclerotic occlusive disease. The plaque tack can be used to hold loose plaque against a blood vessel wall. The plaque tack can include an annular member configured to apply an expansion force to the loose plaque.
The plaque tack 5 can include a plurality of plaque anchors 9 on its outer annular periphery. The plaque anchors 9 can be embedded into or at least placed in physical contact with plaque by expanding up against the plaque. In certain embodiments, the plaque anchors 9 are adapted to elevate adjacent sections of the tack 5 relative to the wall of the vessel. In at least this sense, the anchors 9 may have some of the advantages of focal elevating elements that are discussed in SECTION III below. The anchors 9 exert a holding force on the plaque while minimizing the amount of material surface area in contact with the plaque or blood vessel wall. As another feature, the plaque tack 5 can extend over only a small area in the axial direction of the vessel wall, in order to minimize the amount of foreign structure placed in the blood vessel. For example, each plaque tack 5 can have an axial length L that is only a small fraction of the axial length of a typical stent.
The plaque tack devices of the present application are designed as a minimally invasive approach to tacking loose or dissected atherosclerotic plaque to the wall of the artery, as illustrated in
One or more plaque tacks 5 can be accurately deployed in positions along the length of a plaque accumulation site where specific holding forces are needed to stabilize the site and/or hold pieces of plaque out of the way of blood flow.
The plaque tack device can be delivered into the blood vessel from endovascular insertion. SECTION IV below discusses a variety of delivery methodologies and devices that can be used to deploy plaque tacks. The delivery device for the different embodiments can be the same, or can be different with features specifically designed to deliver the specific tack. The plaque tack and installation procedure may be designed in a number of ways that share a common methodology of utilizing an expansion force of the delivery mechanism (such as balloon expansion) and/or the expansion force of a compressible annular band to enable the tack to be moved into position in the blood vessel, then released, unfolded or unplied to an expanded state within the blood vessel.
Variations of the plaque tack 5 can have a mesh-like configuration and can be arranged with one or more circumferential members formed with discrete struts, such as in open and closed cell constructions, among other designs.
A. Plaque Tack with Metallic Mesh Construction
An embodiment of a plaque tack 10 in the form of a metallic mesh construction is illustrated in
The annular band of the plaque tack 10 can have a dimension in the axial direction of the vessel walls (sometimes referred to herein as length) that is about equal to or less than its expanded diameter, in order to minimize the emplacement of foreign scaffolding structure in the blood vessel. Expanded diameter means final diameter in an unconstrained expansion. One or more tacks can be applied only in positions along the length of a plaque accumulation site where specific holding forces are needed to stabilize the site and/or hold pieces of plaque out of the way of blood flow.
The mesh pattern can be designed so that the plaque tack 10 can be compressed radially inward to a smaller-volume size. This can allow the plaque tack 10 to be loaded onto or within a catheter delivery device to be inserted into the blood vessel. For example, the tack 10 can have an overall circular shape with bends, such as inner V bends, that allow it to be folded in zig-zag fashion to a compressed smaller-volume form for loading in a delivery catheter, such as a deployment tube.
At the desired position in the blood vessel, the compressed plaque tack 10 is released from the delivery catheter. The mesh combined with an annular, ring shape can allow the plaque tack 10 to spring back to its expanded shape. Alternatively, the tack 10 can be expanded by another device, such as by a balloon.
Returning now to
The plaque tack may be made of a material such as a corrosion-resistant metal, polymer, composite or other durable, flexible material. A preferred material is a metal having “shape memory” (such as Nitinol). In some embodiments, a tack may have an axial length of about 0.1 to 6 mm, an expanded diameter of about 1 to 10 mm, and an anchor height from 0.01 to 5 mm. In general, the annular band of the plaque tack has a length in the axial direction of the vessel walls that is about equal to or less than its diameter, in order to minimize the amount of foreign structure to be emplaced in the blood vessel. The annular band can have a ratio of axial length to diameter as low as 1/100.
B. Plaque Tack with Open Cell Construction
The plaque tack 10′ can have features similar to those described above with respect to the plaque tack 10. For example, the plaque tack 10′ may also be laser cut or etched out of a metal tube form. Similarly, the plaque tack 10′ may be made of a material such as a corrosion-resistant metal (e.g., certain coated or uncoated stainless steel or cobalt-chromium alloys), polymer, composite or other durable, flexible material. A preferred material is a metal having “shape memory” (such as Nitinol).
The cells 16 of the tack 10′ can be bounded by portions of two rings 12, which can be mirror images of each other. Thus, some embodiments can be fully described by reference to only one side of the tack 10′ and of the cell 16. The ring 12, a portion of which is illustrated in
The rings 12 can have a plurality of struts or structural members 26, 27, 28, 29. The plurality of struts can repeat about the circumference of the ring 12. The struts can be many different shapes and sizes. The struts can extend in various different configurations. In some embodiments, the plurality of struts 26, 27, 28, 29 extend between inward 18, 19 and outward apices 24, 25.
In some embodiments, the outward apices 24, 25 extend axially different distances as measured from a central zone or midline C of the tack 10′. In particular, the apex 24 can be considered a high apex and the apex 25 can be considered a low apex in this regard. The inward apices 18, 19 may be axially aligned, e.g., being positioned at the same axial distance from the midline C. Thus, the outward apex 24 is disposed farther away from the bridge and inward apices than the outward apex 25. In some embodiments, the axial length of the tack 10′ is measured from the top of the outward apex 24 on one side of the cell 16 to the corresponding top of the outward apex 24 on the other side of the cell. Put another way, the first outward apex 24 extends a first axial distance from the midline C of the tack 10′ and the second outward apex 25 extends a second axial distance from the central zone C of the tack 10′, the first distance being greater than the second distance. Each side of the cell 16 as shown has one high outward apex 24 and one low outward apex 25.
The bridge 14 can be connected to the one or more of the inward apices 18, 19. The bridge 14 can join the two rings 12 together. The bridge 14 can have many different shapes and configurations. Some embodiments of the tack 10′ have a proximal ring and a distal ring with the bridge disposed between and connecting them. As mentioned above, the bridge 14 can be located at the central zone or midline C of the tack 10′. In
As shown, the bridge 14 is connected to each ring at the inward apex 18. In some embodiments, a bridge is connected to every inward apex, forming a closed cell construction. In other embodiments, the bridge 14 is connected to every other inward apex, every third inward apex, or spaced farther apart by as needed, forming a variety of open cell configurations. The number of bridges 14 can be chosen depending upon the application. For example, six or fewer bridges 14 may be used between the two rings 12 when desired for limiting neointimal hyperplasia.
One technique for enhancing the plaque holding capability of the bridges 14 is to align plaque holding structures (such as the barb 9, projections 10b, or the anchors discussed below) with a force application location or direction of the ring 12. In some embodiments, at least a portion of the bridge 14 can be aligned, with one of the struts of the ring 12. For example, where the bridge 14 connects to the ring 12, whether at an inward apex or at a strut, that connecting portion of the bridge can extend therefrom in a manner that is aligned, partially or substantially aligned with a strut.
A series of unique design features can be integrated into the tack 10′ for various purposes as will be discussed in more detail in the sections below. For example, the tack 10′ can include one or more of anchors, markers and focal elevating elements, among other features. As discussed above,
As another example, a series of unique design features can be integrated into the tack 10′ for dynamic distribution of stresses within the tack 10′. These design features can enable the uniform control of the tack 10′ during compression, expansion, delivery, and catheter release. The design features can also individually and/or collectively manage the stresses throughout the bulk of the tack, along the struts, and at the interface of the tack and the blood vessel lumen. Better control of the distribution of stresses within the tack has the benefit of reducing cellular response and tack fracture by limiting strut fatigue and the associated micro-rubbing at the tack-blood vessel interface. Micro-rubbing includes a variety of small scale adverse interactions between implants and patient tissue, such as abrasion or friction that occurs on a cellular or intercellular level between the tack and the blood vessel lumen.
A reduction in cellular response is believed to be achieved partly through a reduction of surface area contact between the tack and the blood vessel lumen and partly by maximizing alignment of the contact points or structures with the blood vessel cells' natural orientation. Thus, the tack is able to move with the blood vessel while decreasing the micro-rubbing. Other devices, such as stents, contact the blood vessel cells in ways that may extend across, e.g., transversely to, multiple cells increasing micro rubbing at the stent-blood vessel interface.
1. Single Column Cell Design
One characteristic of the embodiment the tack 10′ of
In various embodiments, the ratio of the vessel contact area to total treatment zone is less than 50%. In some embodiments, the ratio of the vessel contact area to total treatment zone is even less, e.g., 40% or less. The ratio of the vessel contact area to total treatment zone can be as small as 20% or less. In specific examples, the ratio of the vessel contact area to total treatment zone is 5% or even 2% or less. As discussed below, focal elevating elements can augment this advantageous feature, even further lowering the ratio of the vessel contact area to total treatment zone by providing separation between the vessel wall and at least a portion the circumferential members 12.
In certain methods, a vessel can be treated by implanting a plurality of structures, e.g., plaque tack 10′. The structures have a total contact area with the vessel wall. The total contact area may be the sum of the vessel contact area of the individual structures. In the method, a total treatment zone area can be defined as the surface area between the proximal end of the most proximal structure and the distal end of the distal most structure. In one method, the total contact area is no more than about 55% of the total treatment zone area. More typically, the total contact area is between about 10% and about 30% of the total treatment zone area. In specific examples, the total contact area is no more than 5-10% of the total treatment zone area.
The tack 10′ can also be understood to provide a relatively high open area within its lateral edges compared to stents. Distinct from traditional stents, the track 10′ need not include sufficient metal to provide a scaffolding function, to hold a vessel open. To accomplish many of the contemplated treatments, the tack 10′ can be configured to limit its contact to only a single point or a plurality of discrete points, for example at one or more axial locations. The discrete points can be widely spaced apart, such as by being points on a circumference that are separated by spaces or, when applied, vascular tissue.
In some embodiments, the open area bounded by lateral edges of the tack 10′ dominates the total footprint, as defined above. The open area of the tack 10′ can be defined as the sum of the areas of the cells 16 when the tack 10′ is in the fully expanded configuration, as defined above. The open area should be calculated at the outer circumference of the tack 10′, for example the area extending between the internal lateral edges of each of the struts. In this context, internal lateral edges are those that form at least a part of the boundary of the cells 16. In various embodiments, the sum of the radially outwardly facing surface of the struts of the tack 10′ can be no more than about 25% of the open area of the tack 10′. More typically, the sum of the radially outwardly facing surface of the struts of the tack 10′ is between about 10% to about 20% of the open area of the tack 10′. In other examples, the sum of the radially outwardly facing surface of the struts of the tack 10′ is less than about 2% of the open area of the tack 10′.
A single column design includes arrangements in a plurality of tack cells are oriented circumferentially about a central axis of the tack 10′. Tack cells can come in many configurations, but generally include spaces enclosed by struts and are disposed in the wall surface of the tack. Open cell designs include arrangements in which at least some of a plurality of internally disposed struts of proximal and distal circumferential members are not connected by bridges or axial connectors.
In one embodiment the cell 16 is identical to a plurality of additional cells 16 that would be disposed circumferentially about the central axis of the tack 10′. The number of cells can vary depending on factors such as the size of the vessel(s) for which the tack 10′ is configured, the preferred arrangements of the rings 12, the number of bridges 14 to be provided and other factors.
As discussed above, the tack 10′ can include proximal and distal rings 12 connected by bridges 14. The proximal ring 12 can be disposed at a proximal end of the tack 10′. The distal ring can be disposed at a distal end of the tack 10′. In some embodiments, the distal ring is the distal most aspect of the tack 10′ and the proximal circumferential member is the proximal most aspect of the tack 10′. The bridges 14 can divide an outer surface of the tack 10′ into cells 16 bounded by the bridges 14 and a portion of each of the proximal and distal rings 12. In the embodiment of
As discussed above, the cells 16 can have one of many different shapes and configurations.
Conventional stent designs are generally relatively long (e.g., 4 cm and even up to 20 cm when used in peripheral vasculature) from their distal to proximal ends. Where arranged with circumferentially disposed cells, conventional stents have a large number of columns of cells. These designs are burdened with repeating points of weakness and can generate stresses that become difficult to manage. As the device is put under stress and strain, these conventional stents must find regions of greater pliability within the strut matrix. These strut regions absorb the load throughout the system and under periods of repeated external forces begin to fail, such as through metallurgical friction loading.
The single column configuration of the tack 10′ is not subject to repeated weak point loading due to movement of remote stent portions because the tack does not have to be axially elongated to provide effective tacking treatment. Other benefits that derive from the shortness include reduced friction at the interface with the catheter sheath during delivery and with the blood vessel wall. As discussed above, the stress at the blood vessel wall interface is reduced due to the lack of cell-to-cell dragging or pulling which in turn reduces the potential that the tack will pull or drag adjacent cells increasing cellular inflammation or histological response along the lumen wall. A single column or other axial short configuration also reduces the stress along each strut because the overall length of single column or other axial short structures or configurations are less affected by the anatomical motion (e.g., bending, twisting, and rotating). This results, at least in part, from the anatomy shifting around short structures while longer structures do not allow the anatomy to shift and thus longer structures absorb more forces resulting from this anatomical motion.
Any motion between the surfaces of the tack and the blood vessel can cause rubbing and friction. If the motion is very small it can be described as micro-rubbing, as discussed above. Even micro-rubbing produces a negative effect on both the tack 10′ and the biological cells of the blood vessel. For example, friction occurs when a portion of an implanted object moves while another portion is stationary or moving by a smaller amount. Differential amounts of moving over time weakens the material leading to fracture by processes such as work hardening. The biological cells become irritated by the friction and can respond by producing an inflammation response Inflammation can drive a variety of undesired histological responses including neointimal hyperplasia and restenosis.
2. Controlled Angle of Struts
In a preferred embodiment, the tack 10′ has an expanded outer diameter of 7.5 mm and the first angle α can be 47.65° and the second angle σ can be 35.56°. In such an embodiment, the plaque tack 10′ can be formed from a tube stock with an initial outer diameter 4 mm. The tube stock can be expanded to 7.5 mm and then heat treated in that shape. In some embodiments, the plaque tack 10′ can be made of a shape memory material and the heat treatment step can be to engrain that particular shape into the “memory” of the material. The plaque tack 10′ can then be crimped or compressed and flash frozen in the compressed state to then be loaded onto a delivery device.
A beneficial feature of the tack 10′ is that the angle of the struts as they meet at each apex can be controlled in at least one of an expanded and a contracted state. For example, the internal angles α, σ of the outward apices 24, 25 can be controlled to be within ±5% of a selected nominal value. This control can be achieved for example, in the expanded state during the heat treatment during the manufacture of the plaque tack 10′.
It has been found that control of the angles can beneficially offer relief from imperfections in the manufacturing process. In some cases, the control of other dimensions can be relaxed if these angles are sufficiently well controlled. By controlling these angles, production run quality can be improved. Such control has been found to enable repeatable, uniform, and balanced compressibility of the tack 10′ during the crimping cycle of manufacturing. These factors increase production run repeatability and offer ease of volume manufacturing which results in a reduction in overall cost of the part.
In addition, control of the apex angles allows the plaque tack 10′ to better distribute stresses along the circumferential members or rings 12. The control of apex angles can be used to control or distribute stresses within the ring 12, e.g., uniformly along the length of the struts or non-uniformly to a region that can more robustly respond to stress loading. By distributing stress along the strut, the problematic localized stresses on the tack 10′, such as at vulnerable spots can be avoided during the expansion and crimping processes of manufacturing.
3. Inverse Tapering Struts
In some embodiments, such as that shown in
In a preferred embodiment, the long struts 26, 27 are disposed at a first circumferential location of the tack 10′ adjacent to one of the markers 22. In particular, the strut 26 has a medial end connected to or forming a portion of one of the inward apices 18 and a lateral end disposed away from the inward apex 18. The lateral end is coupled to the strut 27 at or adjacent to the outward apex 24. The strut 26 has a width W4 adjacent to the medial end and a width W2 adjacent to the lateral end. In this embodiment, the width of the strut 26 increases along the length thereof from the width W4 to the width W2. The increase in width along the strut 26 preferably is continuous along this length.
Also, the sides of the struts 26 can be sloped relative to a longitudinal axis LA of the strut 26. For example, a first side 48 disposed between the longitudinal axis of the strut 26 and the strut 27 can be disposed at an angle to (e.g., non-parallel to) the longitudinal axis of the strut 26. In another embodiment, a second side 46 of the strut 26 can be disposed at an angle to (e.g., non-parallel to) the longitudinal axis of the strut 26. In one embodiment, both the first and second sides 46, 48 of the strut can be disposed at angles to the longitudinal axis of the strut 26.
The strut 27 preferably also has different widths at different points along its length. In particular, the strut 27 can be wider in a generally lateral direction adjacent to the outward apex 24 than it is adjacent to the inward apex 19. As discussed above in connection with the strut 26, the strut 27 can have side surfaces that are angled relative to the longitudinal axis of the strut 27. The strut 27 can be tapered between its ends, e.g., having a continuously decreasing width along its length from wider adjacent to the outward apex 24 to narrower adjacent to the inward apex 19.
The strut 28 extends from the strut 27 or inward apex 19. The strut 28 can have a medial end that is wider than a lateral end of the strut 28 and can have different widths at different points along its length. The side surfaces can also be angled relative to the longitudinal axis of the strut 28.
Finally, a strut 29 can be connected to the strut 28 or outward apex 25 at a lateral end of the strut 29. The strut 29 can have a medial end that is wider than the lateral end thereof. The strut 29 can have a taper that is the same or different from the strut 28. For example, the strut 29 can be wider overall than the third strut.
In one embodiment, the strut 26 can have a width W2 of about 0.12 mm at the lateral end near the outward apex 24 and a width W4 of about 0.095 mm at the medial end near the inward apex 18 and the strut 28 can have a width W6 of about 0.082 mm near the outward apex 25 and a width W8 of about 0.092 mm near the inward apex 19. More generally, the change in thickness between W4/W2 expressed as a percentage can be between about 70% and about 90% more typically between about 75% and about 85%, and in certain embodiments about 80%. The tapering can also be inverted, e.g., with the struts tapered from the ends (e.g., lateral edges) toward the medial portion.
A unique inverse taper or variation in width along the strut is achieved by inverting the orientation of the taper between the short struts 28, 29 and the long struts 26, 27. The longer struts 26, 27 go from a narrow width near the inward apices 18, 19 to a broader width near the high outward apex 24. Conversely, the shorter struts 28, 29 are the opposite with a broader width near the inward apices 18, 19 to a narrower width near the low outward apex 25.
Through strategic selection of the width of the struts, as discussed above, the plaque tack can distribute the stresses observed during compression and after deployment. This feature can also contribute to the control of the stress by distributing the region of stress more uniformly along the length of the strut. In some embodiments, it may be desirable to distribute the stress non-uniformly to regions more able to handle the stress.
4. Dual Amplitude Struts
As been discussed above, the ring 12 illustrated in
In some embodiments, the outward apices 24, 25 alternate between a high outward apex 24 and a low outward apex 25. In this context “high” corresponds to a larger distance H1 as measured from a central zone or midline C of the tack 10′ and “low” corresponds to a smaller distance H2 as measured from the midline C (
The varying amplitude of the long and short sinusoidal struts described above can provide additional control of the plaque tack's functionality. In particular, it can enhance compression of the tack 10′ to provide a greater change in circumference from the fully expanded configuration to a compressed configuration when crimped during manufacturing. Greater compressibility facilitates delivery in smaller vessels and a greater range of indication that can be treated because it enables a smaller crossing profile delivery system.
The height H1, H2 of the apices is measured from the center line C to the top of the respective outward apices 24, 25. The dual amplitude sinusoidal patterned plaque tack 10′, such as that shown in
The ranges of compression for the plaque tack 10′ have been measured to 0.25 times nominal tube size in combination with ranges of expansion up to 2 times nominal tube size, although these are not the anticipated limits of the device. Combining these ranges the full range of compression has been measured at 0.125 times the heat treated outer diameter. As discussed above in SECTION II.B.2, in some embodiments the nominal tube size is 4.5 mm and the tube is expanded to 7.5 mm in the manufacturing process. According to some embodiments, the distance from the midline C of the device to the apex of the longer struts H1 is approx. 3.0 mm, while the distance H2 to the apex of the shorter struts is approx. 2.6 mm.
In addition to the enhanced compressibility range, the energy stored in the shorter amplitude struts offers additional control of the plaque tack 10′ during the release phase of delivery within the blood vessel. As the catheter sheath is retracted, the longer struts are uncovered first followed by the shorter struts (
5. Centrally Disposed Anchoring and Elevating Structure
As discussed above, the plaque tack 10′ can be a self-expanding circumferential structure and the anchors 20 can be disposed on an outer portion of the tack. The anchors 20 can be coupled with any portion of the tack 10′ but preferably are disposed adjacent to the midline C of the bridges 14 as discussed above. In one embodiment, the tack 10′ includes two anchors disposed on either side of the midline C as illustrated in
In one aspect, the plaque interaction of the tack 10′ is primarily provided by the anchors 20 and to a lesser extent the bridges 14. In some embodiments, the anchors can have a preferred penetration length into the plaque of 0.01 mm to 5 mm. In certain variations, the penetration length is within a range of about 0.03 mm to about 1 mm. In other variations, the penetration length is within a range of about 0.05 mm to about 0.5 mm. The bridges 14, which can be disposed at alternating inward apices, as discussed above, can be configured to reside on a tangential plane of a cylinder when the tack 10′ is fully expanded and not being deformed by an outward structure. The tangent configuration causes the anchors 20 to project outward toward from the cylindrical surface of the tack 10′. In this outward projecting position, the anchors are adapted to engage plaque or other vascular deposits causing the vessel to vary from its unobstructed fixed state, e.g. to be out-of-round.
The tangential projection of the anchors and bridges also advantageous enhances the control of the tack 10′ upon deployment. A technique for deploying the tack 10′ involves positioning the tack in a hollow catheter body. When positioned in the catheter body, the tack 10′ is compressed to a compressed state. The rings 12 are highly conformal due to their construction, discussed above. As a result, the rings fully appose to the inner luminal surface of the hollow catheter body. In contrast, the bridges 14 and anchors 20 are more rigid and therefore are less conformal and as a result bite into the inner luminal surface of the catheter body. This creates a retention force within the catheter and limits unintended movement of some or all of the tack 10′ toward a catheter deployment zone.
In some embodiments, the retention force of the barbs 20 is maintained or increased after partial deployment of the tack 10′. In particular, a region of relatively high flexibility can be provided at the junction of the bridges 14 and the rings 12. While high flexibility sections of stents can be areas of concern, such is not the case in the plaque tack 10′ for reasons discussed below. The flexible region can have any material property or structure to enhance its flexibility at least compared to that of the bridges 14 such that upon movement of the ring 12 on the leading edge of deployment, the tangential configuration and tendency of the anchors 20 to bite into the hollow elongate catheter body is not diminished. Such is the case even though the leading edge ring 12 may expand to at least one-half of its fully expanded size.
As shown, the bridge 14 is connected to each ring at the inward apex 18 where at least a portion of the bridge 14 can be aligned, partially or substantially aligned with one of the struts that make up the ring 12 as has been described. For example, as shown, the bridge 14 is aligned with a high amplitude sinusoidal section of the pattern. The region of relatively high flexibility can be disposed between the inward apex 18 and the bridge 14.
In certain embodiments, expansion of the ring 12 may even cause the anchors 20 to rotate outward to increase the retention force in the catheter body. For example, expansion of the strut 26 may cause an inward deflection of the inward apex 18. While ring 12 is expanding a slight rotation of anchors 20 may occur which may cause a torqued outward deflection of the leading anchor and a corresponding torqued outward deflection of the trailing anchor. With reference to
The out-of-cylinder nature of the bridges 14 and anchors 20 also provide benefits to the deployed state. In particular, in some embodiments in an expanded state, the plaque anchors 20 are disposed radially outwardly of a cylindrical surface formed by the rings 12. The degree of out-of-cylinder can depend on the application, but in general may be sufficient to space at least a portion of the cylindrical surface from the inner walls of the vasculature when deployed. As such, the anchors 20 or the anchors combined with the rings 12 can be configured as focal elevating elements, which are discussed below in SECTION III.
As the plaque tack 10′ expands within a blood vessel, the struts will engage the vessel wall and/or plaque. It is anticipated that in most situations, at least some of the struts will be deformed in response to irregularities of shape within the blood vessel. At the same time, the bridges 14 are less deformable and thus will resist such deformation retaining a circular configuration. The outward forces that are applied by the strut members are transferred into those areas that are in contact with the blood vessel wall. In some cases, when the tack 10′ conforms to an irregularly shaped blood vessel lumen, the rigid central anchors become the region for blood vessel contact. The cumulative outward force of the struts in the rings 12 are applied through the bridges 14 to the anchors. Adjacent struts share their load with the contact region pressing the blood vessel into an enlarged configuration, such as a conformed circle.
Such a configuration can provide benefits such as helping the plaque tack 10′ to remain in place after delivery and allowing the plaque tack 10′ to respond dynamically to the movement and pulsing of the blood vessel itself. In addition, this configuration can have the benefit of reducing cellular response and device fracture by limiting strut fatigue and associated micro friction loading at the tack-blood vessel interface.
In some embodiments, the bridge 14 can include one or more anchor. In some embodiments, the bridge can be formed entirely of anchors.
After deployment of the plaque tack 10′, the surgeon has the option of placing an angioplasty balloon at the site of the tack and inflating the balloon to press the anchor or anchors 20 into the plaque and/or wall of the blood vessel.
6. Flat Midline Markers
As discussed above, the plaque tack 10′ has one or more markers 22. In one embodiment, a series of radiopaque markers 22 can be located on the tack 10′. In some embodiments, the radiopaque markers 22 are at the midline C of the device. The radiopaque markers 22 can be disposed between the two circumferentially oriented sinusoidal members or rings 12.
In some embodiments, the radiopaque markers 22 (e.g., platinum or tantalum) can be disposed adjacent to the plaque anchors 20. The radiopaque markers 22 can have one of many different shapes or configurations. In some embodiments, the radiopaque markers 22 have a planar or flat structure. As shown in
According to certain delivery methods, due to the co-placement of the anchors 20 and the markers 22 at the bridges 14 between the sinusoidal rings 12, the markers 22 can offer a visible clue to the clinician of the point when the release of the device will take place. For example, once the markers 22 meet a marker strip located at the tip of a delivery catheter sheath the full device can be deployed.
7. Simultaneous Device Placement in the Vessel
The plaque tack 10′ can be configured for simultaneous placement within a blood vessel. Simultaneous placement of the plaque tack 10′ can be defined as the entire plaque tack 10′ being released from the delivery catheter prior to any all of the distal apices of the plaque tack 10′ contacting the blood vessel lumen where it is to be placed. This event can occur when the anchors 20 are completely uncovered by the catheter sheath allowing the entire plaque tack 10′ to expand against the lumen wall of blood vessel. The struts 26, 27, 28, 29 can be free floating, e.g., spaced from the vessel wall or applying negligible force to the wall, such that they do not contact the lumen wall prior to simultaneous placement. For example, the anchors 20 may have the effect of spacing a portion or substantially all of the struts 26, 27, 28, 29 from the vessel wall. Other forms of focal elevating elements are discussed below that can be used to space the tack 10′ from the lumen wall.
Simultaneous placement offers the clinician the ability to control placement up until the markers 22 and/or anchors 20 are uncovered which can generate a full expansion event (struts adjacent to or contacting the lumen wall). In some embodiments, the full expansion event does not occur until the anchors 20 are uncovered due mainly to internal forces of the tack 10′ urging the anchors 20 to engage the delivery sheath described above.
Another benefit of simultaneous placement is the reduction of any inadvertent dragging or pushing of struts against or along the lumen surface during the placement of the plaque tack 10′. Due to the complexity and variation of disease, location of placement, and dissections morphology, the ability of the outer surface of the plaque tack 10′ to contact the lumen wall all at the same time is dependant on the deployment circumstances. However, the ability of the plaque tack 10′ to contact the lumen wall completely upon release from the catheter sheath within fractions of a second has been observed.
8. Low Slope Force Curve
Another unique aspect of the plaque tack 10′ is that it can be configured with a force curve with an extended area having a low slope. A force curve, such as that illustrated in
Still referring to
As can be seen in
The tack is radially self expandable through a range of at least about 2 mm, generally at least about 3 mm and typically through a range of at least about 4 mm or 5 mm, while exhibiting a radial expansion force of no more than about 5 N at any point throughout the range. In some embodiments, the maximum radial expansion force throughout the expansion range is no more than about 4 N and preferably is no more than about 3 N. In one embodiment, the tack is expandable over a range of at least about 3 mm (e.g., from about 3 mm to at least about 6 mm) and the radial expansion force is less than about 3 throughout that range. Generally the change in expansion force will be no more than about 3 N and preferably no more than about 2 N throughout the expansion range. In one embodiment, the expansion force drops from no more than about 2 N at 3 mm diameter to no more than about 1 N at 6 mm diameter. Typically the difference between the radial force of compression and the radial expansion force at any given diameter throughout the expansion range is no more than about 4 N, generally no more than about 3 N, preferably no more than about 2 N and in one embodiment is no more than about 1 N. In one implementation, the tack is expandable throughout a range which includes 3 mm through about 6.5 mm and the difference between the compression force and expansion force at each point along the compression/expansion range differs by no more than about 2 N and preferably by no more than about 1 N.
In general, the outward force of the plaque tack 10′ is preferred to be as low as possible, while providing sufficient force to hold the plaque against the lumen wall through a wide range of luminal diameters. When force is elevated, e.g., by two to three times the sufficient holding force, adverse side effects can occur. These can include irritating the cells of the vessel wall that are in contact with the device, which can lead to re-stenosis. Although a very low force device is preferred for the typical treatment, higher force devices may be useful where loose plaque is found at calcified lesions.
One advantage to having a slow change in force as the device is expanding is the ability to predict the energy that the blood vessel experiences independent of the lumen diameter. Another value would be the reduction of necessary inventory for hospitals. For instance, it has been found that two part sizes of the tack 10′ shown in
C. Plaque Tack Design Parameters
One purpose of the plaque tack described herein, as distinct from traditional stenting, is to reduce the amount of implanted foreign material to a minimum while still performing focal treatment of the blood vessel condition so as to cause a minimum of blood vessel wall reaction and adverse post-treatment restenosis. The plaque tack is designed to have substantially less metal coverage and/or contact with the blood vessel surface, thereby inciting less acute and chronic inflammation (See
The plaque tack can be deployed only where needed to tack down plaque that has been disrupted by balloon angioplasty or other mechanisms. Rather than cover an entire area of treatment, the plaque tack can be placed locally and selectively, for example, not extending into normal or less diseased artery segments (See
One parameter for design of a plaque tack is having a tack axial length to expanded diameter (L/D) ratio of no more than about 2.0, often no more than about 1.5 and in some implementations no more than about 1. In one embodiment, the tack has about an L/D ratio of 0.8. That is, the length of the tack along the axis of the blood vessel is about equal to or less than the expanded diameter of the tack. The preferred plaque tack is thus shaped like an annular ring or band, whereas the typical stent is shaped like an elongated tube. The small-profile tack can thus be used locally for targeted treatment of disrupted regions of the blood vessel surface with a minimum of foreign material coverage or contact. Tests show that a plaque tack with an axial length/diameter ratio 1 causes almost no biological reaction or subsequent blood vessel narrowing in comparison to a traditional stent where the axial length is greater than the diameter, and usually much greater. Tests indicate that device L/D1 results in a reduction in scaffolding much less than that of the typical stent and causes less arterial wall reaction. For application at sites of small dissection after balloon angioplasty, a plaque tack of minimal footprint may be used such as a single, thin ring-type tack with an L/D ratio in the range of 1/10 to 1/100.
Studies on stenting have shown that the axial length of a stent is correlated with a tendency for occlusion in multiple vascular territories. The more stent axial length that has been placed, the higher likelihood that the reconstruction will fail. The axial length of a stent is also directly linked to the frequency and tendency of the stent to break when placed in the superficial femoral artery. The medical literature indicates that the superficial femoral artery performs like a rubber band, and it is likely that changes to the natural elongation and contraction of the superficial femoral artery play a significant role in the failure mode of superficial femoral artery stents. In contrast, the small-profile plaque tack can be implanted only in local areas requiring their use, thereby enabling the blood vessel to retain its natural flexibility to move and bend even after the surface has undergone tacking. Multiple tacks may be implanted separated by regions free of metallic support, thereby leaving the artery free to bend more naturally.
Outward radial pressure exerted on the blood vessel wall can also be substantially reduced by the small-profile tack design, even when multiple tacks are used in a spaced-apart configuration. To minimize this outward force while still providing the required retention of dissections against the arterial wall, a series of anchor barbs or focal elevating elements can be utilized. The presence of these features applying focal pressure to the wall of the artery allows the rest of the tack to apply minimum outward force to the artery wall. The points which apply the pressure can be very focal, and this is where the most force is applied. The focal nature of the application of the pressure exerted by the tack also minimizes the structural effects of the device. Uniformly distributed anchors or focal elevating elements can provide a distribution of radial energy maximizing the tendency to form a circular lumen.
Another important parameter for design of a plaque tack is the ratio of Vessel Coverage Area (C) to Total Vessel Surface area (TVS). In one definition, the value C is the length of the prosthesis (e.g., stent or tack) times the average circumference of the vessel in which it is placed and the value TVS can be the length of the lesion or area requiring treatment times the same nominal circumference. This can also be simplified to a ratio of total length of the prosthesis when expanded to the nominal circumference divided by the length of the lesion in the vessel. These concepts can be applied to one tack device or when several spaced-apart tack devices are placed across the length of a blood vessel treatment area. Where multiple stents or tacks are used, a simplified ratio could be total non-overlapping length divided by lesion length or could be the sum of the length of the prostheses divided by the sum of the length(s) of the lesion(s). For a plaque tack, the C/TVS ratio is in the range of about 60% or less, whereas for a stent it can be 100% or more (if applied to overlap the treatment site).
For a focal lesion, the conventional treated vessel length is X+10 mm to 20 mm where X is the length of the lesion and the added length is adjoining on normal or less diseased artery proximal or distal to the lesion. In traditional stenting the entire treated vessel length would be covered with a stent. For example, in the case of a 2 cm lesion, the treated vessel length would be 3 to 4 cm (usually a single stent of this length would be selected), so that C/TVS is 150%-200%. In contrast, with tack placement about ½ of X would be covered, and none of the adjoining normal or less diseased artery would be treated. For example, in a 2 cm lesion, approximately 1 cm would be covered, so that the C/TVS ratio is about 60% or less. An advantageous aspect of this innovative approach is placement of bands only in regions of dissections requiring vascular tacking.
As described previously, in some embodiments, a tack device 10′ is formed with rings or mesh bands 12 connected by longitudinal bridge members 14 (
When two or more stents need to be employed over an extended length of treatment site, it has been a conventional practice to overlap adjoining stents to prevent kinking between stents. Due to the increased metal lattice, the region of overlap becomes highly rigid and noncompliant. This noncompliant doubly rigid region further limits the natural arterial flexibility and increases the tendency for restenosis. Stent fractures occur more frequently in the superficial femoral artery where this bending has a high frequency and are common when multiple stents are deployed and overlap. Stent fractures are associated with a higher risk of in-stent restenosis and re-occlusion. In contrast, the plaque tacks are designed to be applied in local areas and not to be overlapped. Optimal spacing is a minimum of l tack axial length apart for tacks. This permits the artery to maintain its flexibility, and only a half or less of the treated length of the artery will be covered with metal. It should be noted that in the case where restenosis occurs after tack placement the overlapping of the entire treated length with a stent still allows the stent to retain its patency. This is due to the repeated pattern of regions where no tacks are placed offering regions of relief and the artery to flex.
The literature in the industry has noted that important factors in stent design may be the ratio of Relative Metal Surface Area (RMS) and the number of longitudinal segments in the device structure, for example, as presented by Mosseri M, Rozenman Y, Mereuta A, Hasin Y, Gotsman M., “New Indicator for Stent Covering Area”, in Catheterization and Cardiovascular Diagnosis, 1998, v. 445, pp. 188-192. More particularly, for a given metal surface area, a higher number of longitudinal segments (each of which is thinner) can reduce the size of the gap between adjacent segments, reducing the tendency for prolapse. As adapted from the RMS measure, an equation for Effective Metallic Interface (EMI) may be used to compare the embodiment of the tack device with longitudinal bridging members to a typical stent, as follows:
Where x is the number of sections of metal, l is an individual metal section length, w is an individual metal section width, C is the vessel coverage area underneath the device (lumen surface), and n is the number of bridge members longitudinally connected between circumferentially oriented segments. The summation found in the denominator can be interpreted as the total metal surface area. The embodiment of the tack device with longitudinal bridging members has an EMI≤10, whereas the EMI of a typical stent would be several times greater. This low EMI is due to the nature of the tack design having a small foot-print and minimal longitudinal bridges while a stent typically has a large foot-print and would be a multiple several times that.
To further reduce the EMI through the inclusion of lift-off-bump features (such as anchors, barbs, or focal elevating elements), an improved EMIF can be obtained for the Tack Effective Metal Interface as provided with floating elements (see
Where all variables are the same as those in the EMI equation with the addition of lF is an individual metal section length that is not in contact with the artery (floating off the artery), and wF is the width of the same section. If no floating sections exist then nF=0 and lFwF=0 and therefore EMIF=EMI.
The inclusion of metal sections that are floating (floating length lF, floating width WF, and number of floating bridges nF) reduces the EMI further which is captured mathematically as a summation with negative variables in the EMIF equation.
The presence on the plaque tack of lift-off-bump features (such as anchors, barbs, or focal elevating elements) minimizes the pressure of the overall structure upon the blood vessel wall by transferring regional outward forces to focal pressure points, thereby applying a higher pressure at the focal points. The presence of the lift-off-bump features applying focal pressure to the artery wall allows the rest of the tack to apply minimum outward force to the artery wall. Wherever the lift-off-bump features are placed, the outward radial energy is maximized at that region, producing a slight outward bowing of the arterial wall. The outward bowing can be used for arterial shaping or molding, for example, 5 or more uniformly distributed focal points can be used to form a circular lumen. Circular lumens offer additional benefit from the standpoint of the vessel wall interaction, independent of the vascular injury.
In any of the embodiments herein described, the plaque tack device may be made from Nitinol, silicon composite (with or without an inert coating), polyglycolic acid, or some other superelastic material, as well as stainless steel, tantalum, a cobalt chromium alloy, bioabsorbable or bioresorbable materials (including bioabsorbable/bioresorbable metals) or a polymer. The strip of material can be created from ribbon, round or rectangular wire or a sheet of material processed through photolithographic processing, laser or water cutting, chemical etching or mechanical removal of the final shape, or the use of bottom up fabrication, for instance chemical vapor deposition processes, or the use of injection modeling, hot embossing, or the use of electro or electroless-plating. It may be fabricated from metal, plastic, ceramic, or composite material.
The plaque tack device is designed to be inherently self-aligning, i.e., its mechanical installation can accommodate small misalignments. By reducing stress in the strut members while gripping the arterial wall in the center of the design, the tack self aligns with the arterial longitudinal axis. Design features that offer stress relief and provide uniform distribution of the unfolding struts include narrow spacing of the anchors, non-uniformly thick struts, and anchors heads that are angled to reduce device from springing forward during delivery. As discussed above, circumferentially oriented anchors located at each bridge member offer gripping force with the catheter tip and embedding features when lying on the artery wall. These design features serve to facilitate placing the tacks in specific locations within diseased blood vessels.
In particular, the high outward apex 24′ formed by the struts 26 and 27 is bent or turned upwards, or radially outwards, to form a focal elevating element (FEE) 32.
A plaque tack devices may be provided with focal elevating elements on the annular periphery of the device. The focal elevating elements are distinguished from the anchors and barbs generally having greater plaque or arterial wall penetration to anchor or stabilize the tack in the blood vessel.
The focal elevating elements may or may not penetrate but still offer regional strut elevation and are preferably placed at apices of struts or periodically along (e.g., perpendicular to) strut lengths. For both anchors and focal elevating elements the size of the interface between the tack and the arterial wall is preferably equal to or shorter than the strut width in at least one direction. The focal elevating elements can be similar to anchors but either do not penetrate or penetrate the tissue only slightly, thereby minimizing the amount of material surface area in contact with the plaque, and offer a set of relief sections for the outward pressure of the tack device adjacent to the focal elevating elements, thereby minimizing the friction generated at the blood vessel wall.
The focal elevating elements can be formed and configured on the annular periphery of the tack device in a similar manner as described for the previous tack device embodiments and can include the raised contact sections in addition to anchors or sharp points. The contact sections can provide improved tacking characteristics in that they increase the contact forces at the contact sections by compressing the plaque at the contact regions and decrease the outward force at the sections neighboring the focal elevating element. This offers regional pressure relief in some sections and increase contact pressure at the bumps or sharp points collectively offering a reduction in trauma and cellular response of the blood vessel wall.
Because the tack device is held in place by its own pressure exerted on the blood vessel surface, it is susceptible to friction, including slight movement between the device and the vessel surface. Every time the organ moves (e.g., the leg during ambulation), the artery moves. It can be inferred that when the artery moves the working device sitting within the artery also moves but not necessarily every point of contact moves in synch with each other. Whenever there is even a small mismatch in movement between the artery and the device the artery and device rub against each other promoting cellular reaction and device failure. It has been deduced from experimental that this rubbing may irritate the endothelium causing an inflammatory response. In some embodiments, strategically placed focal elevating elements (FEEs) are implemented to reduce the overall regional friction load (thought to be a source of inflammation, cellular proliferation, and the healing response that leads to restenosis) of the area being held open.
As an example, a blood vessel such as the popliteal that is cyclically shortened and elongated is believed to have a cellular or tissue structures that elongate and compress in a direction parallel to the axis of the vessel. The natural behavior of this cellular or tissue structure involves a significant amount of local movement along this axial direction. If an implant to be placed in such a vessel is designed to contact the vessel wall in a direction transverse to this axial direction, the natural behavior of these tissues or cells will be greatly disrupted. For example, the tissue will be constrained and the natural movement will be greatly reduced. Also, rubbing can occur along the edges of the transversely contacting structure, resulting in friction and/or abrasion of the tissue and corresponding inflammation. FEEs, in contrast, reduce the disruption of the natural behavior of the tissue or cells. If incorporated into a tack device or other prosthesis, FEEs can focus the contact at zones that are spaced apart along a direction transverse to the predominant direction of motion (e.g., the axial direction in the case of the popliteal or similar vessel). Between these zones of focused contact corresponding to the FEEs, the interaction of the compressing and elongating tissue or cells with the structure of the implant is greatly reduced. In this in-between zone, the motion between the compressing and elongating tissue or cells can approach that of the tissue or cells before the implantation of the prosthesis. Raised sections produced by the FEEs limit the histological response of the tissue and also the fatigue of the device by limiting the contact between the device and the tissue.
Independent of the overall amount of contact and number of FEEs, the tack devices smooth the lumen wall, and allow more natural vessel movement. Where FEEs offer the greatest value is in their ability to reduce the amount of interaction between tissue or cells that move, elongate or compress, which can produce rubbing or friction to such tissue or cells. It is this highly localized movement or “micro-movement” that increases the cellular response of the blood vessel surface to the foreign device.
The focal elevating elements are designed to reduce effective metal interface (EMI) by minimizing the overall material contact with the blood vessel surface. The focal elevating element (FEE) is preferably configured as a narrow, lifted feature with enough height to lift adjacent strut sections of the tack device off from contact with the arterial wall in order to reduce the surface area of foreign material in contact with the arterial wall. Reducing the contact burden is of particular value when the strut members are connecting circumferential rings or circumferentially oriented strut bands. Strut sections oriented against the natural grain of the cellular orientation that are in contact with the blood vessel walls can produce microfriction when they move or rub against the blood vessel walls. By reducing the foreign material contact area against the blood vessel wall, the tendency for production of microfriction contact is reduced.
Referring to
One or more of the features labeled in
Any of the foregoing dimensions of h may be combined with a variety of dimensions of W of the FEE. The W dimension would typically be the width of the strut but could be as little of 50% the strut width and may be between about 50% and about 100% the width of the struts at the location of the FEE. If and Ia are a function of W, the radial force of the system, the topography of the lumen, and the delivery device, e.g., varied if a balloon is used to press the device into the artery. If we just look at W (non elastic system) then Ia may be about equal to the length of the strut. As outward force (both from the elastic nature of the metal and the balloon assist) increases then Ia can be reduced, approaching 0. However, in various embodiments, Ia is at least about 20 um.
The focal elevating elements may be formed as cylindrical, rectangular, linear, spherical, conical, tear dropped, pyramidal, or inclined elements on the annular periphery of the tack device. They can be formed by bending or stamping a section of the tack structure, by an additive process (such as by welding or annealing on a peripheral surface), by a subtractive process (such as by grinding or etching away surrounding material so that the bump element is higher than the surrounding surface), or by modifying small sections of the peripheral surface to be higher than the surrounding surface before or after sheet or tube cutting. For example, one method of modification of small sections of a mesh tack structure is by knotting, twisting, bending or weaving small sections of the wire mesh to produce raised elements from the mesh surface which are the interface with the artery wall of the tack devices.
Properly oriented and symmetrically positioned focal elevating elements can provide foci for expansion force. As the device exerts outward forces and the artery exerts inward forces, the focal elevating elements can be positioned at strategically located positions reducing the outward pressure of strut sections neighboring the focal elevating elements.
Both anchors and focal elevating elements can offer strategic advantages that include: the reduction in pressure burden across the tack struts by reducing the contact area and translating the outward forces to the anchors and focal elevating elements, minimizing surface contact which offers a reduction in the tendency of frictional loading driven by micro movement between the arterial wall and the tack strut, and the stabilization of anchoring the tack where the anchor or focal elevating element penetrates the vessel wall a fraction of the features height.
Because the tack device is held in place by its own outward force pressure exerted on the plaque and blood vessel surface, it may be susceptible to friction, i.e., slight movement between the device and the vessel surface.
The number and locations of focal elevating elements can affect the overall Relative Metal Surface Area (RMS) which was explained previously. The focal elevating elements may be positioned along the lengths of the tack device surfaces such that a minimal amount of metal surface area is in contact with the artery wall. Focal elevating elements placed at bridges between circumferential strut rings or at the apices of strut sections of the tack device can offer a majority of arterial injury relief. When focal elevating elements are placed only at apices and bridges, the RMS of the strut members making up the concentric ring changes a little while the RMS of the bridges is reduced more significantly, due to the narrow length, offering relief of relative motion of the circumferentially oriented strut rings.
Inherent in the use of shape memory alloys for the tack devices is the ability to conform to the shape of the blood vessel walls. Because the focal elevating elements can exert an expansion pressure on the blood vessel walls with a minimal risk of injury, they can be designed to reshape the blood vessel walls to a desired shape.
A variety of delivery methodologies and devices that can be used to deploy plaque tacks, some of which are described below. For example, a plaque tack can be delivered into the blood vessel with an endovascular insertion. The delivery devices for the different embodiments of plaque tacks can be different or the same and can have features specifically designed to deliver the specific tack. The plaque tack and installation procedure may be designed in a number of ways that share a common methodology of utilizing an expansion force of the delivery mechanism (such as balloon expansion) and/or the expansion force of a compressible annular band to enable the tack to be moved into position in the blood vessel, then released, unfolded or unplied to an expanded state within the blood vessel.
Referring back to
It can be seen that the plaque tack 10 can be positioned in a patient's vasculature at a treatment site by the delivery device 11. The outer sheath 13 can be withdrawn or retracted to expose and release the plaque tack 10. The tack 10 can then be expanded in any suitable way, such as by being configured to self-expand or to be balloon expanded, as discussed herein.
Turning now to
While widening the vessel 7, a dissection 44 of the plaque may be caused by the angioplasty (
A delivery catheter 11′ preloaded with one or more tacks 10″ can be advanced along the guidewire 40 to the treatment site (
The tack 10″ can then be released in the desired location in the lumen. As discussed previously, simultaneous placement can result upon release of some embodiments of the plaque tack 10″. Additional plaque tacks 10″ can then be placed as desired (
While a three tack construct formed in situ may be suitable for certain indications, an intravascular construct having at least 5 intravascular tacks may be advantageous for treating loose plaque, vessel flaps, dissections or other maladies that are significantly more elongated (non focal). For example, while most dissections are focal (e.g., axially short), a series of dissections may be considered and treated as a more elongated malady.
In some cases, even shorter axial length tack can be used to treat even more spaced apart locations. For example, a plurality of tacks each having a length of no more than about 7 mm can be placed in a vessel to treat a tackable malady. At least some of, e.g., each of, the tacks can be spaced apart from an adjacent tack by at least about 5 mm. In some cases, it may be preferred to provide gaps between adjacent tacks that can range from about 6 mm to about 10 mm.
Optionally, once the plaque tacks 10″ are in place, the angioplasty balloon can be returned to the treatment site and inflated to expand the plaque tacks 10″ to the desired state of expansion.
Referring to
Use of Plaque Tack after Drug Eluting Balloon Angioplasty
The use of plaque tack devices can be combined with use of drug eluting balloon (DEB) angioplasty to manage post angioplasty dissection and avoid the need for stents. In DEB angioplasty, a drug-eluting balloon or a drug coated balloon is prepared in a conventional manner. The drug may be one, or a combination, of biologically active agents that are used for various functions, such as anti-thrombotic, anti-mitotic, anti-proliferative, anti-inflammatory, stimulative of healing, or other functions. The DEB is delivered on a guidewire across an area of blockage or narrowing in the blood vessel system. The DEB is inflated to a specific pressure and for a period of time consistent with the manufactures guidelines of use for treatment purposes, as it pertains the drug coating and the intended outcomes, then the DEB is deflated and removed. At this stage the medication from the DEB has been transferred to the wall of the blood vessel. Intravascular imaging by ultrasound is then used to assess the integrity of the artery and the smoothness of the blood vessel surface at the site where the balloon was inflated. The presence of damage along the surface may be indicated as dissection, elevation of plaque, disruption of tissue, irregularity of surface. The plaque tack is used to tack down the damaged, disrupted, dissected, or irregular blood vessel surface. This permits continuation of a “stent-free” environment even if damage to the blood vessel has occurred as a result of balloon angioplasty.
At this stage the medication from the DEB has been transferred to the wall of the blood vessel. Contrast is administered into the blood vessel under fluoroscopic guidance or another method such as intravascular ultrasound is used to assess the integrity of the artery and the smoothness of the blood vessel surface at the site where the balloon was inflated. In some cases, one or more of these completion studies will demonstrate the presence of damage along the surface at the site of the balloon inflation. This damage may include dissection, elevation of plaque, disruption of tissue, irregularity of surface.
The plaque tack delivery catheter is loaded with multiple tacks that may be placed at the discretion of the operator, and advanced over a guidewire in the blood vessel to the location where the dissection or disruption or irregularity has occurred. The location is specifically and carefully identified using angiography. The plaque tack(s) is or are deployed at the location(s) of the lesion. More than one tack may be placed to tack down a major dissection. If more than one tack is placed, it may be placed only according to the rules of proper spacing of tacks. That is, the tack should be at least one tack axial length apart. After placement of the tack, it may be further expanded into the wall of the blood vessel using a standard angioplasty balloon or a drug-eluting or drug coated balloon (either as a stand alone (separate) device or integral to the delivery system). The purpose of the tack is generally not to hold the blood vessel lumen open but to tack down the non-smooth or dissected surface of the blood vessel. This “touch-up strategy” permits the resolution of the damage created by the drug-eluting or drug coated balloon without resorting to stent placement and thereby maintaining a “stent-free” environment.
As a further measure, described above, the plaque tack device itself can be used to deliver medication to the blood vessel. In addition to the delivery of medication from the anchors, the tack can be coated with medication prior to tack placement. The purpose of this activity is to permit the tack to elute biologically active agent or agents that have positive effects on the blood vessel.
One or more of the tacks deployed in accordance with the present invention may be coated with or otherwise carry a drug to be eluted over time at the deployment site. Any of a variety of therapeutically useful agents may be used, including but not limited to, for example, agents for inhibiting restenosis, inhibiting platelet aggregation, or encouraging endothelialization. Some of the suitable agents may include smooth muscle cell proliferation inhibitors such as rapamycin, angiopeptin, and monoclonal antibodies capable of blocking smooth muscle cell proliferation; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, acetyl salicylic acid, and mesalamine, lipoxygenase inhibitors; calcium entry blockers such as verapamil, diltiazem and nifedipine; antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, methotrexate, doxorubicin, daunorubicin, cyclosporine, cisplatin, vinblastine, vincristine, colchicine, epothilones, endostatin, angiostatin, Squalamine, and thymidine kinase inhibitors; L-arginine; antimicrobials such as triclosan, cephalosporins, aminoglycosides, and nitorfuirantoin; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; nitric oxide (NO) donors such as lisidomine, molsidomine, NO-protein adducts, NO-polysaccharide adducts, polymeric or oligomeric NO adducts or chemical complexes; anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, enoxaparin, hirudin, Warfarin sodium, Dicumarol, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet factors; interleukins, interferons, and free radical scavengers; vascular cell growth promoters such as growth factors, growth factor receptor antagonists, transcriptional activators, and translational promotors; vascular cell growth inhibitors such as growth factor inhibitors (e.g., PDGF inhibitor—Trapidil), growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; Tyrosine kinase inhibitors, chymase inhibitors, e.g., Tranilast, ACE inhibitors, e.g., Enalapril, MMP inhibitors, (e.g., Ilomastat, Metastat), GP IIb/IIIa inhibitors (e.g., Integrilin, abciximab), seratonin antagonist, and 5-HT uptake inhibitors; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms. Polynucleotide sequences may also function as anti-restenosis agents, such as p15, p16, p18, p19, p21, p2′7, p53, p5′7, Rb, nFkB and E2F decoys, thymidine kinase (“TK”) and combinations thereof and other agents useful for interfering with cell proliferation. The selection of an active agent can be made taking into account the desired clinical result and the nature of a particular patient's condition and contraindications. With or without the inclusion of a drug, any of the tacks disclosed herein can be made from a bioabsorbable material. Various polymeric carriers, binding systems or other coatings to permit controlled release of active agent from the tack or its coating are well known in the coronary stent arts and not reproduced herein.
In summary, the plaque tack can be used for plaque retention following balloon angioplasty treatment of atherosclerotic occlusive disease while avoiding problems with the use of stents due to installing a large mass of foreign material in the body which may cause injury, inflammation, and/or provide sites for restenosis. In contrast with stents, the plaque tack device minimizes the material structure while only being installed at one or more plaque dissection sites that require retention. The focal elevating elements on the tack periphery minimizes the contact surface area of the plaque tack with the blood vessel walls and reduces the risk of causing plaque dissection or injury to the blood vessel walls. This approach offers clinicians the ability to perform a minimally invasive post-angioplasty treatment and produce a stent-like result without using a stent.
Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Additionally, it is contemplated that various aspects and features of the invention described can be practiced separately, combined together, or substituted for one another, and that a variety of combination and sub-combinations of the features and aspects can be made and still fall within the scope of the invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims.
This application is a continuation of U.S. patent application Ser. No. 15/170,772, filed Jun. 1, 2016, now U.S. Pat. No. 10,278,839, which is a continuation of U.S. patent application Ser. No. 13/153,257, filed Jun. 3, 2011, now U.S. Pat. No. 9,375,327. U.S. patent application Ser. No. 13/153,257 is a continuation-in-part of U.S. patent application Ser. No. 12/790,819, filed May 29, 2010, now U.S. Pat. No. 10,188,533. U.S. patent application Ser. No. 12/790,819 is a continuation-in-part of U.S. patent application Ser. No. 12/483,193, filed Jun. 11, 2009, now U.S. Pat. No. 8,128,677. All of the above applications are incorporated by reference herein and are to be considered a part of this specification. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3221746 | Noble | Dec 1965 | A |
| 3635223 | Klieman | Jan 1972 | A |
| 4292974 | Fogarty et al. | Oct 1981 | A |
| 4446867 | Leveen et al. | May 1984 | A |
| 4465072 | Taheri | Aug 1984 | A |
| 4515587 | Schiff | May 1985 | A |
| 4545367 | Tucci | Oct 1985 | A |
| 4545390 | Leary | Oct 1985 | A |
| 4552127 | Schiff | Nov 1985 | A |
| 4576591 | Kay et al. | Mar 1986 | A |
| 4589412 | Kensey | May 1986 | A |
| 4641654 | Samson et al. | Feb 1987 | A |
| 4651738 | Demer et al. | Mar 1987 | A |
| 4687465 | Prindle et al. | Aug 1987 | A |
| 4723550 | Bales et al. | Feb 1988 | A |
| 4723936 | Buchbinder et al. | Feb 1988 | A |
| 4723938 | Goodin et al. | Feb 1988 | A |
| 4726374 | Bales et al. | Feb 1988 | A |
| 4758223 | Rydell | Jul 1988 | A |
| 4762130 | Fogarty et al. | Aug 1988 | A |
| 4781192 | Demer | Nov 1988 | A |
| 4784636 | Rydell | Nov 1988 | A |
| 4846174 | Willard et al. | Jul 1989 | A |
| 4848342 | Kaltenbach | Jul 1989 | A |
| RE33166 | Samson | Feb 1990 | E |
| 5009659 | Hamlin et al. | Apr 1991 | A |
| 5024668 | Peters et al. | Jun 1991 | A |
| 5042707 | Taheri | Aug 1991 | A |
| 5047015 | Foote et al. | Sep 1991 | A |
| 5102390 | Crittenden et al. | Apr 1992 | A |
| 5196024 | Barath | Mar 1993 | A |
| 5201757 | Heyn et al. | Apr 1993 | A |
| 5242452 | Inoue | Sep 1993 | A |
| 5246420 | Kraus et al. | Sep 1993 | A |
| 5250029 | Lin et al. | Oct 1993 | A |
| 5250060 | Carbo et al. | Oct 1993 | A |
| 5263962 | Johnson et al. | Nov 1993 | A |
| 5269758 | Taheri | Dec 1993 | A |
| 5304121 | Sahatjian | Apr 1994 | A |
| 5318529 | Kontos | Jun 1994 | A |
| 5336234 | Virgil et al. | Aug 1994 | A |
| 5344397 | Heaven et al. | Sep 1994 | A |
| 5383890 | Miraki et al. | Jan 1995 | A |
| 5397305 | Kawula et al. | Mar 1995 | A |
| 5397355 | Marin et al. | Mar 1995 | A |
| 5421955 | Lau et al. | Jun 1995 | A |
| 5423851 | Samuels | Jun 1995 | A |
| 5423885 | Williams | Jun 1995 | A |
| 5501689 | Green et al. | Mar 1996 | A |
| 5534007 | St. Germain et al. | Jul 1996 | A |
| 5536252 | Imran et al. | Jul 1996 | A |
| 5540659 | Teirstein | Jul 1996 | A |
| 5545135 | Iacob et al. | Aug 1996 | A |
| 5562728 | Lazarus et al. | Oct 1996 | A |
| 5569272 | Reed et al. | Oct 1996 | A |
| 5571135 | Fraser et al. | Nov 1996 | A |
| 5591197 | Orth et al. | Jan 1997 | A |
| 5593417 | Rhodes | Jan 1997 | A |
| 5616149 | Barath | Apr 1997 | A |
| 5634928 | Fischell et al. | Jun 1997 | A |
| 5643312 | Fischell et al. | Jul 1997 | A |
| 5665116 | Chaisson et al. | Sep 1997 | A |
| 5681346 | Orth et al. | Oct 1997 | A |
| 5704913 | Abele et al. | Jan 1998 | A |
| 5725572 | Lam et al. | Mar 1998 | A |
| 5728158 | Lau et al. | Mar 1998 | A |
| 5743874 | Fischell et al. | Apr 1998 | A |
| 5746716 | Vigil et al. | May 1998 | A |
| 5746764 | Green et al. | May 1998 | A |
| 5776161 | Globerman | Jul 1998 | A |
| 5797951 | Mueller | Aug 1998 | A |
| 5800526 | Anderson et al. | Sep 1998 | A |
| 5813977 | Hinchliffe et al. | Sep 1998 | A |
| 5817152 | Birdsall et al. | Oct 1998 | A |
| 5829662 | Allen et al. | Nov 1998 | A |
| 5833694 | Poncet | Nov 1998 | A |
| 5843033 | Ropiak | Dec 1998 | A |
| 5911725 | Boury | Jun 1999 | A |
| 5925061 | Ogi et al. | Jul 1999 | A |
| 5928247 | Barry et al. | Jul 1999 | A |
| 5954742 | Osypka | Sep 1999 | A |
| 5957949 | Leonhardt et al. | Sep 1999 | A |
| 5968068 | Dehdashtian et al. | Oct 1999 | A |
| 5968088 | Hansen et al. | Oct 1999 | A |
| 5972023 | Tanner et al. | Oct 1999 | A |
| 5980552 | Pinchasik et al. | Nov 1999 | A |
| 6004328 | Solar | Dec 1999 | A |
| 6007543 | Ellis et al. | Dec 1999 | A |
| 6009614 | Morales | Jan 2000 | A |
| 6013854 | Moriuchi | Jan 2000 | A |
| 6022374 | Imran | Feb 2000 | A |
| 6036725 | Avellanet | Mar 2000 | A |
| 6048360 | Khosravi et al. | Apr 2000 | A |
| 6053941 | Lindenberg et al. | Apr 2000 | A |
| 6053943 | Edwin et al. | Apr 2000 | A |
| 6080177 | Igaki | Jun 2000 | A |
| 6090135 | Plaia et al. | Jul 2000 | A |
| 6110198 | Fogarty et al. | Aug 2000 | A |
| 6123722 | Fogarty et al. | Sep 2000 | A |
| 6126685 | Lenker et al. | Oct 2000 | A |
| 6129754 | Kanesaka et al. | Oct 2000 | A |
| 6139573 | Sogard et al. | Oct 2000 | A |
| 6143016 | Bleam et al. | Nov 2000 | A |
| 6146358 | Rowe | Nov 2000 | A |
| 6152937 | Peterson et al. | Nov 2000 | A |
| 6157852 | Selmon et al. | Dec 2000 | A |
| 6165199 | Barbut | Dec 2000 | A |
| 6187034 | Frantzen | Feb 2001 | B1 |
| 6197013 | Reed | Mar 2001 | B1 |
| 6197103 | Davies et al. | Mar 2001 | B1 |
| 6200336 | Pavcnik et al. | Mar 2001 | B1 |
| 6203568 | Lombardi et al. | Mar 2001 | B1 |
| 6203569 | Wijay | Mar 2001 | B1 |
| 6221102 | Baker et al. | Apr 2001 | B1 |
| 6241667 | Vetter et al. | Jun 2001 | B1 |
| 6254628 | Wallace et al. | Jul 2001 | B1 |
| 6258117 | Camrud et al. | Jul 2001 | B1 |
| 6266550 | Selmon et al. | Jul 2001 | B1 |
| 6270524 | Kim | Aug 2001 | B1 |
| 6273909 | Kugler et al. | Aug 2001 | B1 |
| 6290728 | Phelps et al. | Sep 2001 | B1 |
| 6312444 | Barbut | Nov 2001 | B1 |
| 6312460 | Drasler et al. | Nov 2001 | B2 |
| 6325824 | Limon | Dec 2001 | B2 |
| 6344053 | Boneau | Feb 2002 | B1 |
| 6364901 | Inoue | Apr 2002 | B1 |
| 6364904 | Smith | Apr 2002 | B1 |
| 6371962 | Ellis et al. | Apr 2002 | B1 |
| 6387113 | Hawkins et al. | May 2002 | B1 |
| 6402777 | Globerman | Jun 2002 | B1 |
| 6409752 | Boatman et al. | Jun 2002 | B1 |
| 6409863 | Williams et al. | Jun 2002 | B1 |
| 6425915 | Khosravi et al. | Jul 2002 | B1 |
| 6428550 | Vargas et al. | Aug 2002 | B1 |
| 6428566 | Holt | Aug 2002 | B1 |
| 6475237 | Drasler et al. | Nov 2002 | B2 |
| 6485510 | Camrud et al. | Nov 2002 | B1 |
| 6491707 | Makower et al. | Dec 2002 | B2 |
| 6508822 | Peterson et al. | Jan 2003 | B1 |
| 6517573 | Pollock et al. | Feb 2003 | B1 |
| 6520984 | Garrison et al. | Feb 2003 | B1 |
| 6527800 | McGuckin, Jr. et al. | Mar 2003 | B1 |
| 6547817 | Fischell et al. | Apr 2003 | B1 |
| 6551353 | Baker et al. | Apr 2003 | B1 |
| 6599296 | Gillick et al. | Jul 2003 | B1 |
| 6623521 | Steinke et al. | Sep 2003 | B2 |
| 6629994 | Gomez et al. | Oct 2003 | B2 |
| 6635083 | Cheng et al. | Oct 2003 | B1 |
| 6648911 | Sirhan et al. | Nov 2003 | B1 |
| 6660031 | Tran et al. | Dec 2003 | B2 |
| 6676698 | McGuckin, Jr. et al. | Jan 2004 | B2 |
| 6692504 | Kurz et al. | Feb 2004 | B2 |
| 6699274 | Stinson | Mar 2004 | B2 |
| 6699277 | Freidberg et al. | Mar 2004 | B1 |
| 6706061 | Fischell et al. | Mar 2004 | B1 |
| 6716240 | Fischell et al. | Apr 2004 | B2 |
| 6719775 | Slaker et al. | Apr 2004 | B2 |
| 6723119 | Pinchasik et al. | Apr 2004 | B2 |
| 6730116 | Wolinsky et al. | May 2004 | B1 |
| 6746475 | Rivelli, Jr. | Jun 2004 | B1 |
| 6752828 | Thornton | Jun 2004 | B2 |
| 6755854 | Gillick et al. | Jun 2004 | B2 |
| 6786922 | Schaeffer | Sep 2004 | B2 |
| 6790221 | Monroe et al. | Sep 2004 | B2 |
| 6790227 | Burgermeister | Sep 2004 | B2 |
| 6810882 | Langberg et al. | Nov 2004 | B2 |
| 6814752 | Chuter | Nov 2004 | B1 |
| 6827731 | Armstrong et al. | Dec 2004 | B2 |
| 6843400 | Lee | Jan 2005 | B1 |
| 6846323 | Yip et al. | Jan 2005 | B2 |
| 6849087 | Chuter | Feb 2005 | B1 |
| 6863685 | Davila et al. | Mar 2005 | B2 |
| 6896697 | Yip et al. | May 2005 | B1 |
| 6899718 | Gifford, III et al. | May 2005 | B2 |
| 6899914 | Schaldach et al. | May 2005 | B2 |
| 6913600 | Valley et al. | Jul 2005 | B2 |
| 6942680 | Grayzel et al. | Sep 2005 | B2 |
| 6942689 | Majercak | Sep 2005 | B2 |
| 6945992 | Goodson, IV et al. | Sep 2005 | B2 |
| 6951554 | Johansen et al. | Oct 2005 | B2 |
| 6986784 | Weiser et al. | Jan 2006 | B1 |
| 7001422 | Escamilla et al. | Feb 2006 | B2 |
| 7001424 | Patel et al. | Feb 2006 | B2 |
| 7007698 | Thornton | Mar 2006 | B2 |
| 7018402 | Vito et al. | Mar 2006 | B2 |
| 7025791 | Levine et al. | Apr 2006 | B2 |
| 7037330 | Rivelli, Jr. et al. | May 2006 | B1 |
| 7041130 | Santini, Jr. et al. | May 2006 | B2 |
| 7052511 | Weldon | May 2006 | B2 |
| 7087088 | Berg et al. | Aug 2006 | B2 |
| 7105016 | Shiu et al. | Sep 2006 | B2 |
| 7122043 | Greenhalgh et al. | Oct 2006 | B2 |
| 7137993 | Acosta et al. | Nov 2006 | B2 |
| 7147655 | Chermoni | Dec 2006 | B2 |
| 7147656 | Andreas et al. | Dec 2006 | B2 |
| 7147661 | Chobotov et al. | Dec 2006 | B2 |
| 7150745 | Stern et al. | Dec 2006 | B2 |
| 7160312 | Saadat | Jan 2007 | B2 |
| 7163552 | Diaz | Jan 2007 | B2 |
| 7166125 | Baker et al. | Jan 2007 | B1 |
| 7169158 | Sniffin et al. | Jan 2007 | B2 |
| 7169163 | Becker | Jan 2007 | B2 |
| 7179284 | Khosravi et al. | Feb 2007 | B2 |
| 7192440 | Andreas et al. | Mar 2007 | B2 |
| 7201770 | Johnson et al. | Apr 2007 | B2 |
| 7208002 | Shelso | Apr 2007 | B2 |
| 7211101 | Carley et al. | May 2007 | B2 |
| 7243408 | Vietmeier | Jul 2007 | B2 |
| 7258697 | Cox et al. | Aug 2007 | B1 |
| 7261731 | Patel et al. | Aug 2007 | B2 |
| 7267684 | Rolando et al. | Sep 2007 | B2 |
| 7270673 | Yee et al. | Sep 2007 | B2 |
| 7273492 | Cheng et al. | Sep 2007 | B2 |
| 7279007 | Nikolic et al. | Oct 2007 | B2 |
| 7296577 | Lashinski et al. | Nov 2007 | B2 |
| 7300456 | Andreas et al. | Nov 2007 | B2 |
| 7294146 | Chew et al. | Dec 2007 | B2 |
| 7303572 | Meisheimer et al. | Dec 2007 | B2 |
| 7306617 | Majercak | Dec 2007 | B2 |
| 7309341 | Ortiz et al. | Dec 2007 | B2 |
| 7309350 | Landreville et al. | Dec 2007 | B2 |
| 7316711 | Allen et al. | Jan 2008 | B2 |
| 7320702 | Hammersmark et al. | Jan 2008 | B2 |
| 7323006 | Andreas et al. | Jan 2008 | B2 |
| 7323007 | Sano | Jan 2008 | B2 |
| 7326236 | Andreas et al. | Feb 2008 | B2 |
| 7329279 | Haug et al. | Feb 2008 | B2 |
| 7331987 | Cox | Feb 2008 | B1 |
| 7331990 | Gianotti | Feb 2008 | B2 |
| 7331992 | Randall et al. | Feb 2008 | B2 |
| 7351255 | Andreas | Apr 2008 | B2 |
| 7399307 | Evans et al. | Jul 2008 | B2 |
| 7402168 | Sanderson et al. | Jul 2008 | B2 |
| 7431729 | Chanduszko | Oct 2008 | B2 |
| 7445631 | Salaheih et al. | Nov 2008 | B2 |
| 7476245 | Abbate | Jan 2009 | B2 |
| 7500986 | Lye et al. | Mar 2009 | B2 |
| 7510575 | Spenser et al. | Mar 2009 | B2 |
| 7524330 | Berreklouw | Apr 2009 | B2 |
| 7537607 | Gerberding | May 2009 | B2 |
| 7556647 | Drews et al. | Jul 2009 | B2 |
| 7578840 | Schaeffer | Aug 2009 | B2 |
| 7604662 | Cambronne et al. | Oct 2009 | B2 |
| 7617007 | Williams et al. | Nov 2009 | B2 |
| 7618432 | Pedersen et al. | Nov 2009 | B2 |
| 7618447 | Case et al. | Nov 2009 | B2 |
| 7625399 | Case et al. | Dec 2009 | B2 |
| 7628803 | Pavcnik et al. | Dec 2009 | B2 |
| 7637935 | Pappas et al. | Dec 2009 | B2 |
| 7655034 | Mitchell et al. | Feb 2010 | B2 |
| 7658759 | Case et al. | Feb 2010 | B2 |
| 7666216 | Hogendijk et al. | Feb 2010 | B2 |
| 7686824 | Konstantino et al. | Mar 2010 | B2 |
| 7695507 | Rivelli, Jr. et al. | Apr 2010 | B2 |
| 7720521 | Chang et al. | May 2010 | B2 |
| 7736387 | Pollock et al. | Jun 2010 | B2 |
| 7758594 | Lamson et al. | Jul 2010 | B2 |
| 7758627 | Richter | Jul 2010 | B2 |
| 7758632 | Hojeibane et al. | Jul 2010 | B2 |
| 7763063 | Arbefeuille et al. | Jul 2010 | B2 |
| 7806918 | Nissl et al. | Oct 2010 | B2 |
| 7810223 | Hemerick et al. | Oct 2010 | B2 |
| 7828834 | Garbe | Nov 2010 | B2 |
| 7833262 | McGuckin, Jr. et al. | Nov 2010 | B2 |
| 7842080 | Chouinard | Nov 2010 | B2 |
| 7846194 | Hartley et al. | Dec 2010 | B2 |
| 7867267 | Sullivan et al. | Jan 2011 | B2 |
| 7871431 | Gurm et al. | Jan 2011 | B2 |
| 7883537 | Grayzel et al. | Feb 2011 | B2 |
| 7896911 | Schneider et al. | Mar 2011 | B2 |
| 7905913 | Chew et al. | Mar 2011 | B2 |
| 7922755 | Acosta et al. | Apr 2011 | B2 |
| 7933660 | Carr | Apr 2011 | B2 |
| 7942920 | Majercak | May 2011 | B2 |
| 7955315 | Feinberg et al. | Jun 2011 | B2 |
| 7963987 | Melsheimer et al. | Jun 2011 | B2 |
| 7967855 | Furst et al. | Jun 2011 | B2 |
| 7972373 | Contiliano et al. | Jul 2011 | B2 |
| 8002725 | Hogendijk | Aug 2011 | B2 |
| 8024851 | Barr et al. | Sep 2011 | B2 |
| 8034099 | Pellegrini | Oct 2011 | B2 |
| 8043354 | Greenberg et al. | Oct 2011 | B2 |
| 8043357 | Hartley | Oct 2011 | B2 |
| 8048151 | O'Brien et al. | Nov 2011 | B2 |
| 8052738 | Craven | Nov 2011 | B2 |
| 8057543 | O'Brien et al. | Nov 2011 | B2 |
| 8092468 | Hansen | Jan 2012 | B2 |
| 8127422 | Wu | Mar 2012 | B2 |
| 8128677 | Schneider et al. | Mar 2012 | B2 |
| 8157851 | Andreas | Apr 2012 | B2 |
| 8177831 | Andreas | May 2012 | B2 |
| 8236045 | Benichou et al. | Aug 2012 | B2 |
| 8292938 | Case | Oct 2012 | B2 |
| 8308790 | Arbefeuille et al. | Nov 2012 | B2 |
| 8317859 | Snow et al. | Nov 2012 | B2 |
| 8323243 | Schneider et al. | Dec 2012 | B2 |
| 8328864 | Niermann | Dec 2012 | B2 |
| 8353945 | Andreas et al. | Jan 2013 | B2 |
| 8366766 | Berreklouw | Feb 2013 | B2 |
| 8394139 | Roeder et al. | Mar 2013 | B2 |
| 8403978 | Schlun et al. | Mar 2013 | B2 |
| 8414636 | Nabulsi et al. | Apr 2013 | B2 |
| 8460357 | McGarry et al. | Jun 2013 | B2 |
| 8474460 | Barrett et al. | Jul 2013 | B2 |
| 8500787 | Simpson et al. | Aug 2013 | B2 |
| 8500789 | Wuebbeling et al. | Aug 2013 | B2 |
| 8540760 | Paul, Jr. et al. | Sep 2013 | B2 |
| 8585747 | Andreas et al. | Nov 2013 | B2 |
| 8652198 | Andreas et al. | Feb 2014 | B2 |
| 8740973 | Furst et al. | Jun 2014 | B2 |
| 8745842 | Wu | Jun 2014 | B2 |
| 8771335 | Griego et al. | Jul 2014 | B2 |
| 8778010 | Venturelli et al. | Jul 2014 | B2 |
| 8784467 | Connelly et al. | Jul 2014 | B2 |
| 8864811 | Kao | Oct 2014 | B2 |
| 8888841 | Pandelidis et al. | Nov 2014 | B2 |
| 8900289 | Thompson | Dec 2014 | B2 |
| 8956398 | George et al. | Feb 2015 | B2 |
| 8961583 | Hojeibane et al. | Feb 2015 | B2 |
| 8966736 | Wu | Mar 2015 | B2 |
| 8986362 | Snow et al. | Mar 2015 | B2 |
| 9050181 | Hartley | Jun 2015 | B2 |
| 9101500 | Feld et al. | Aug 2015 | B2 |
| 9101503 | Lowe et al. | Aug 2015 | B2 |
| 9113999 | Taylor et al. | Aug 2015 | B2 |
| 9216082 | Von Segesser et al. | Dec 2015 | B2 |
| 9237959 | Cage | Jan 2016 | B2 |
| 9301864 | Kao | Apr 2016 | B2 |
| 9370437 | Chuter et al. | Jun 2016 | B2 |
| 9375327 | Giasolli et al. | Jun 2016 | B2 |
| 9398967 | Cornelius | Jul 2016 | B2 |
| 9452067 | Wu | Sep 2016 | B2 |
| 9480826 | Schneider et al. | Nov 2016 | B2 |
| 9545322 | Schneider et al. | Jan 2017 | B2 |
| 9585777 | Pacetti | Mar 2017 | B2 |
| 9603730 | Giasolli et al. | Mar 2017 | B2 |
| 9603980 | Zhao | Mar 2017 | B2 |
| 9707115 | Masakazu | Jul 2017 | B2 |
| 9730818 | Giasolli et al. | Aug 2017 | B2 |
| 9737368 | Lumauig | Aug 2017 | B2 |
| 9918835 | Guyenot et al. | Mar 2018 | B2 |
| 9974670 | Schneider et al. | May 2018 | B2 |
| 10022250 | Giasolli | Jul 2018 | B2 |
| 10117762 | Giasolli et al. | Nov 2018 | B2 |
| 10137013 | Giasolli et al. | Nov 2018 | B2 |
| 10166127 | Giasolli et al. | Jan 2019 | B2 |
| 10188533 | Schneider et al. | Jan 2019 | B2 |
| 10245167 | Longo | Apr 2019 | B2 |
| 10245168 | Amendt et al. | Apr 2019 | B2 |
| 10271973 | Giasolli et al. | Apr 2019 | B2 |
| 10278839 | Giasolli et al. | May 2019 | B2 |
| 10285831 | Giasolli et al. | May 2019 | B2 |
| 10292845 | Higashi et al. | May 2019 | B2 |
| 10299945 | Schneider et al. | May 2019 | B2 |
| 10390977 | Giasolli et al. | Aug 2019 | B2 |
| 10660771 | Giasolli et al. | May 2020 | B2 |
| 20020120323 | Thompson | Aug 2002 | A1 |
| 20020123790 | White et al. | Sep 2002 | A1 |
| 20020165599 | Nasralla | Nov 2002 | A1 |
| 20020169495 | Gifford et al. | Nov 2002 | A1 |
| 20030055491 | Schwartz et al. | Mar 2003 | A1 |
| 20030069630 | Burgermeister et al. | Apr 2003 | A1 |
| 20030130720 | DePalma et al. | Jul 2003 | A1 |
| 20030220683 | Minasian et al. | Nov 2003 | A1 |
| 20030225446 | Hartley | Dec 2003 | A1 |
| 20030225448 | Gerberding | Dec 2003 | A1 |
| 20040010307 | Grad et al. | Jan 2004 | A1 |
| 20040186551 | Kao et al. | Sep 2004 | A1 |
| 20040186558 | Pavcnik et al. | Sep 2004 | A1 |
| 20040215324 | Vonderwalde et al. | Oct 2004 | A1 |
| 20040260389 | Case et al. | Dec 2004 | A1 |
| 20040267348 | Gunderson et al. | Dec 2004 | A1 |
| 20050010275 | Sahatjian et al. | Jan 2005 | A1 |
| 20050096731 | Looi et al. | May 2005 | A1 |
| 20050149163 | Sahota | Jul 2005 | A1 |
| 20050246008 | Hogendijk et al. | Nov 2005 | A1 |
| 20050251164 | Gifford, III et al. | Nov 2005 | A1 |
| 20050278011 | Peckham | Dec 2005 | A1 |
| 20050288764 | Snow et al. | Dec 2005 | A1 |
| 20050288766 | Plain et al. | Dec 2005 | A1 |
| 20060047297 | Case | Mar 2006 | A1 |
| 20060069424 | Acosta et al. | Mar 2006 | A1 |
| 20060074478 | Feller, III | Apr 2006 | A1 |
| 20060111769 | Murray | May 2006 | A1 |
| 20060184225 | Pryor | Aug 2006 | A1 |
| 20060184227 | Rust | Aug 2006 | A1 |
| 20060206190 | Chermoni | Sep 2006 | A1 |
| 20060248698 | Hanson et al. | Nov 2006 | A1 |
| 20060282149 | Kao | Dec 2006 | A1 |
| 20070021826 | Case | Jan 2007 | A1 |
| 20070088420 | Andreas et al. | Apr 2007 | A1 |
| 20070093744 | Elmaleh | Apr 2007 | A1 |
| 20070156223 | Vaughan | Jul 2007 | A1 |
| 20070156225 | George et al. | Jul 2007 | A1 |
| 20070156226 | Chew et al. | Jul 2007 | A1 |
| 20070179587 | Acosta et al. | Aug 2007 | A1 |
| 20070191926 | Nikanorov et al. | Aug 2007 | A1 |
| 20080033522 | Grewe et al. | Feb 2008 | A1 |
| 20080051867 | Davila et al. | Feb 2008 | A1 |
| 20080077229 | Andreas et al. | Mar 2008 | A1 |
| 20080082154 | Tseng et al. | Apr 2008 | A1 |
| 20080132999 | Mericle et al. | Jun 2008 | A1 |
| 20080208327 | Rowe | Aug 2008 | A1 |
| 20080221658 | Martin et al. | Sep 2008 | A1 |
| 20080255653 | Schkolnik | Oct 2008 | A1 |
| 20080264102 | Berra | Oct 2008 | A1 |
| 20080269865 | Snow et al. | Oct 2008 | A1 |
| 20080319528 | Yribarren et al. | Dec 2008 | A1 |
| 20090076594 | Sabaria | Mar 2009 | A1 |
| 20090082841 | Zacharias et al. | Mar 2009 | A1 |
| 20090149943 | Tower | Jun 2009 | A1 |
| 20090216284 | Chin et al. | Aug 2009 | A1 |
| 20090248139 | Pellegrini | Oct 2009 | A1 |
| 20090248141 | Shandas et al. | Oct 2009 | A1 |
| 20090270965 | Sinha et al. | Oct 2009 | A1 |
| 20090270967 | Fleming, III et al. | Oct 2009 | A1 |
| 20090276031 | Kao | Nov 2009 | A1 |
| 20100131045 | Globerman et al. | May 2010 | A1 |
| 20100137966 | Magnuson | Jun 2010 | A1 |
| 20100228333 | Drasler et al. | Sep 2010 | A1 |
| 20100318173 | Kolandaivelu et al. | Dec 2010 | A1 |
| 20110004237 | Schneider et al. | Jan 2011 | A1 |
| 20110077731 | Lee et al. | Mar 2011 | A1 |
| 20110230954 | Schneider et al. | Sep 2011 | A1 |
| 20120016457 | Chobotov et al. | Jan 2012 | A1 |
| 20120035705 | Giasolli et al. | Feb 2012 | A1 |
| 20120083872 | Schneider et al. | Apr 2012 | A1 |
| 20120191176 | Nagl et al. | Jul 2012 | A1 |
| 20130144375 | Giasolli et al. | Jun 2013 | A1 |
| 20140194967 | Schneider et al. | Jul 2014 | A1 |
| 20140288629 | Amendt | Sep 2014 | A1 |
| 20170000629 | Giasolli et al. | Jan 2017 | A1 |
| 20170181873 | Schneider et al. | Jun 2017 | A1 |
| 20170319361 | Giasolli et al. | Nov 2017 | A1 |
| 20170319364 | Jung et al. | Nov 2017 | A1 |
| 20170367856 | Tanaka et al. | Dec 2017 | A1 |
| 20180110634 | Giasolli et al. | Apr 2018 | A1 |
| 20180200085 | Giasolli et al. | Jul 2018 | A1 |
| 20180200086 | Giasolli et al. | Jul 2018 | A1 |
| 20180200087 | Giasolli et al. | Jul 2018 | A1 |
| 20180207008 | Giasolli et al. | Jul 2018 | A1 |
| 20190192319 | Giasolli et al. | Jun 2019 | A1 |
| 20190192321 | Schneider et al. | Jun 2019 | A1 |
| 20190282381 | Giasolli et al. | Sep 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 2008335140 | Nov 2012 | AU |
| 2011274392 | Nov 2013 | AU |
| 2014201067 | Mar 2014 | AU |
| 2010259907 | Aug 2015 | AU |
| 2013212056 | Jul 2016 | AU |
| 2015207895 | May 2017 | AU |
| 2014280976 | Jul 2017 | AU |
| 2705275 | Jul 2013 | CA |
| 1856280 | Nov 2006 | CN |
| 101102728 | Jan 2008 | CN |
| 101262835 | Sep 2008 | CN |
| 101754727 | Jun 2010 | CN |
| 101909552 | Dec 2010 | CN |
| 102292036 | Dec 2011 | CN |
| 102724931 | Oct 2012 | CN |
| 103313682 | Sep 2013 | CN |
| 104220026 | Dec 2014 | CN |
| 104887365 | Sep 2015 | CN |
| 103313682 | Aug 2016 | CN |
| 104220026 | Sep 2016 | CN |
| 106466205 | Mar 2017 | CN |
| 106473786 | Mar 2017 | CN |
| 106473849 | Mar 2017 | CN |
| 107028691 | Aug 2017 | CN |
| 107157632 | Sep 2017 | CN |
| 107205834 | Sep 2017 | CN |
| 104887365 | Dec 2017 | CN |
| 60030705 | May 2007 | DE |
| 10 2009 041 025 | Mar 2011 | DE |
| 20 2011 107 781 | Dec 2011 | DE |
| 20 2011 110 714 | Dec 2015 | DE |
| 10 2014 016 588 | May 2016 | DE |
| 20 2011 110 818 | Sep 2016 | DE |
| 2775968 | Dec 2017 | DK |
| 0497620 | Aug 1992 | EP |
| 0714640 | Jun 1996 | EP |
| 0855883 | Aug 1998 | EP |
| 0812580 | Feb 2004 | EP |
| 1393766 | Mar 2004 | EP |
| 1236446 | Aug 2005 | EP |
| 1803423 | Jul 2007 | EP |
| 1894545 | Mar 2008 | EP |
| 1452151 | Oct 2008 | EP |
| 1378212 | Sep 2009 | EP |
| 2219535 | Aug 2010 | EP |
| 2440155 | Apr 2012 | EP |
| 1786367 | Apr 2013 | EP |
| 1973502 | Apr 2014 | EP |
| 2806826 | Dec 2014 | EP |
| 2881086 | Jun 2015 | EP |
| 2699207 | Oct 2015 | EP |
| 2590602 | Dec 2015 | EP |
| 3015078 | May 2016 | EP |
| 3058900 | Aug 2016 | EP |
| 1689327 | Sep 2016 | EP |
| 3072463 | Sep 2016 | EP |
| 2775968 | Sep 2017 | EP |
| 3217927 | Sep 2017 | EP |
| 2714816 | Jul 1995 | FR |
| 201106757 | Jun 2011 | GB |
| H06-000221 | Jan 1994 | JP |
| H08-332229 | Dec 1996 | JP |
| H11-501526 | Feb 1999 | JP |
| H11-506665 | Jun 1999 | JP |
| 2007-503923 | Mar 2007 | JP |
| 2008-504078 | Feb 2008 | JP |
| 2008-246214 | Oct 2008 | JP |
| 2008-537891 | Oct 2008 | JP |
| 2010-516333 | May 2010 | JP |
| 2015-506760 | Mar 2015 | JP |
| 2016-135278 | Jul 2016 | JP |
| 6006808 | Oct 2016 | JP |
| 10-2017-0084214 | Jul 2017 | KR |
| WO 1996002211 | Feb 1996 | WO |
| WO 1996009013 | Mar 1996 | WO |
| WO 1996037167 | Nov 1996 | WO |
| WO 1999048440 | Sep 1999 | WO |
| WO 1999049440 | Sep 1999 | WO |
| WO 2000066034 | Nov 2000 | WO |
| WO 2001076509 | Oct 2001 | WO |
| WO 2002034163 | May 2002 | WO |
| WO 2003047651 | Jun 2003 | WO |
| WO 2003101310 | Dec 2003 | WO |
| WO 2004006983 | Jan 2004 | WO |
| WO 2004032799 | Apr 2004 | WO |
| WO 2006005082 | Jan 2006 | WO |
| WO 2006026371 | Mar 2006 | WO |
| WO 2007088549 | Aug 2007 | WO |
| WO 2007109621 | Sep 2007 | WO |
| WO 2009076517 | Jun 2009 | WO |
| WO 2010037141 | Apr 2010 | WO |
| WO 2010118432 | Oct 2010 | WO |
| WO 2010144845 | Dec 2010 | WO |
| WO 2011153110 | Dec 2011 | WO |
| WO 2012006602 | Jan 2012 | WO |
| WO 2012143731 | Oct 2012 | WO |
| WO 2013068127 | May 2013 | WO |
| WO 2013112768 | Aug 2013 | WO |
| WO 2016074799 | May 2016 | WO |
| Entry |
|---|
| Bosiers, M. et al., “Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty”, Journal of Vascular Surgery, vol. 64, Jul. 2016, in 8 pages. |
| Kokkinidis, D. et al., “Emerging and Future Therapeutic Options for Femoropopliteal and Infrapopliteal Endovascular Intervention”, Interventional Cardiology Clinics, vol. 6, 2017, in 17 pages. |
| Shishehbor, M. et al., “Endovascular Treatment of Femoropopliteal Lesions”, Journal of the American College of Cardiology, vol. 66, 2015, in 4 pages. |
| Zeller, T. et al., “Novel Approaches to the Management of Advanced Peripheral Artery Disease: Perspectives on Drug-Coated Balloons, Drug-Eluting Stents, and Bioresorbable Scaffolds”, Current Cardiology Reports, vol. 17, Sep. 2015, in 6 pages. |
| International Preliminary Report on Patentability, re PCT Application No. PCT/US2008/086396, dated Jun. 15, 2010. |
| International Preliminary Report on Patentability, re PCT Application No. PCT/US2011/038468, dated Dec. 13, 2012. |
| International Preliminary Report on Patentability, re PCT Application No. PCT/US2011/043471, dated Jan. 17, 2013. |
| International Preliminary Report on Patentability, re PCT Application No. PCT/US2013/023030, dated Aug. 7, 2014. |
| Colombo et al., “Intravascular Ultrasound-Guided Percutaneous Transluminal Coronary Angioplasty With Provisional Spot Stenting for Treatment of Long Coronary Lesions”, Journal of the American College of Cardiology, vol. 38, No. 5, Nov. 1, 2001. |
| Mosseri et al., “New Indicator for Stent Covering Area”, in Catheterization and Cardiovascular Diagnosis, 1998, vol. 44, pp. 188-192. |
| Australian Office Action (Notice of Acceptance), re AU Application No. 2011274392, dated Nov. 14, 2013, including accepted (allowed) claims. |
| Australian Office Action, re AU Application No. 2008335140, dated Apr. 21, 2011. |
| Australian Office Action, re AU Application No. 2008335140, dated Mar. 15, 2011. |
| Australian Office Action, re AU Application No. 2011274392, dated May 3, 2013. |
| European Office Action and Supplemental European Search Report, re EP Application No. 11804455.1, dated Jun. 11, 2014. |
| European Office Action and Supplementary Partial European Search Report, re EP Application No. 08858824.9, dated Sep. 27, 2012. |
| International Search Report and Written Opinion, re PCT Application No. PCT/US2010/038379, dated Feb. 25, 2011. |
| International Search Report and Written Opinion, re PCT Application No. PCT/US2011/038468, dated Jan. 18, 2012. |
| International Search Report and Written Opinion, re PCT Application No. PCT/US2013/023030, dated Apr. 16, 2013. |
| International Search Report and Written Opinion, re PCT Application PCT/US2008/086396, dated Jul. 27, 2009. |
| International Search Report and Written Opinion, re PCT Application PCT/US2011/043471, dated Feb. 9, 2012. |
| International Search Report, re PCT Application No. PCT/US2013/023030, dated Apr. 16, 2013. |
| English translation of the first Office Action and Search Report in Chinese Application No. 201610546800.2 in 5 pages dated Sep. 28, 2017. |
| English translation of the first Office Action and Search Report in Chinese Application No. 201610546643.5 in 5 pages dated Oct. 17, 2017. |
| U.S. Appl. No. 11/955,331 (U.S. Pat. No. 7,896,911), filed Dec. 12, 2007 (Mar. 1, 2011), Device and Method for Tacking Plaque to Blood Vessel Wall. |
| U.S. Appl. No. 13/038,175 (U.S. Pat. No. 9,545,322), filed Mar. 1, 2011 (Jan. 17, 2017), Device and Method for Tacking Plaque to Blood Vessel Wall. |
| U.S. Appl. No. 15/375,026, filed Dec. 9, 2016, Device and Method for Tacking Plaque to Blood Vessel Wall. |
| U.S. Appl. No. 12/483,193 (U.S. Pat. No. 8,128,677), filed Jun. 11, 2009 (Mar. 6, 2012), Device and Method for Tacking Plaque to a Blood Vessel Wall. |
| U.S. Appl. No. 13/246,776 (U.S. Pat. No. 9,974,670), filed Sep. 27, 2011 (May 22, 2018), Method of Treating Atherosclerotic Occlusive Disease. |
| U.S. Appl. No. 15/984,111 (U.S. Pat. No. 10,299,945), filed May 18, 2018 (May 28, 2019), Method of Treating Atherosclerotic Occlusive Disease. |
| U.S. Appl. No. 14/102,411, filed Dec. 10, 2013, Method of Treating Atherosclerotic Occlusive Disease. |
| U.S. Appl. No. 12/790,819 (U.S. Pat. No. 10,188,533), filed May 29, 2010 (Jan. 29, 2019), Minimal Surface Area Contact Device for Holding Plaque to Blood Vessel Wall. |
| U.S. Appl. No. 16/259,146, filed Jan. 28, 2019, Minimal Surface Area Contact Device for Holding Plaque to Blood Vessel Wall. |
| U.S. Appl. No. 13/118,388, filed May 28, 2011, Stent Device Having Focal Elevating Elements for Minimal Surface Area Contact With Lumen Walls. |
| U.S. Appl. No. 13/179,458 (U.S. Pat. No. 10,022,250), filed Jul. 8, 2011 (Jul. 17, 2018), Deployment Device for Placement of Multiple Intraluminal Surgical Staples. |
| U.S. Appl. No. 15/815,515, filed Nov. 16, 2017, Deployment Device for Placement of Multiple Intraluminal Surgical Staples. |
| U.S. Appl. No. 15/921,464, filed Mar. 14, 2018, Deployment Device for Placement of Multiple Intraluminal Surgical Staples. |
| U.S. Appl. No. 13/153,257 (U.S. Pat. No. 9,375,327), filed Jun. 3, 2011 (Jun. 28, 2016), Endovascular Implant. |
| U.S. Appl. No. 15/170,772 (U.S. Pat. No. 10,278,839), filed Jun. 1, 2016 (May 7, 2019), Endovascular Implant. |
| U.S. Appl. No. 15/921,448 (U.S. Pat. No. 10,285,831), filed Mar. 14, 2018 (May 14, 2019), Endovascular Implant. |
| U.S. Appl. No. 15/921,459 (U.S. Pat. No. 10,390,977), filed Mar. 14, 2018 (Aug. 27, 2019), Endovascular Implant. |
| U.S. Appl. No. 15/921,477 (U.S. Pat. No. 10,271,973), filed Mar. 14, 2018 (Apr. 30, 2019), Endovascular Implant. |
| U.S. Appl. No. 16/426,627, filed May 30, 2019, Endovascular Implant and Deployment Devices. |
| U.S. Appl. No. 13/749,643 (U.S. Pat. No. 9,730,818), filed Jan. 24, 2013 (Aug. 15, 2017), Endoluminal Device and Method. |
| U.S. Appl. No. 14/089,703 (U.S. Pat. No. 9,603,730), filed Nov. 25, 2013 (Mar. 28, 2017), Endoluminal Device and Method. |
| U.S. Appl. No. 15/472,215, filed Mar. 28, 2017, Endoluminal Device and Method. |
| U.S. Appl. No. 15/654,586 (U.S. Pat. No. 10,117,762), filed Jul. 19, 2017 (Nov. 6, 2018), Endoluminal Device and Method. |
| U.S. Appl. No. 15/837,870 (U.S. Pat. No. 10,137,013), filed Dec. 11, 2017 (Nov. 27, 2018), Endoluminal Device and Method. |
| U.S. Appl. No. 15/921,541 (U.S. Pat. No. 10,166,127), filed Mar. 14, 2018 (Jan. 1, 2019), Endoluminal Device and Method. |
| U.S. Appl. No. 16/225,528, filed Dec. 19, 2018, Endoluminal Device and Method. |
| U.S. Appl. No. 13/939,019, filed Jul. 10, 2013, Systems and Methods for Attaching Radiopaque Markers to a Medical Device. |
| U.S. Appl. No. 14/746,636 (U.S. Pat. No. 9,192,500), filed Jun. 22, 2015 (Nov. 24, 2015), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 14/885,295 (U.S. Pat. No. 9,375,337), filed Oct. 16, 2015 (Jun. 28, 2016), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/133,709, filed Apr. 20, 2016, Delivery Device and Method of Delivery. |
| U.S. Appl. No. 14/935,087 (U.S. Pat. No. 9,345,603), filed Nov. 6, 2015 (May 24, 2016), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/133,751 (U.S. Pat. No. 9,602,786), filed Apr. 20, 2016 (Mar. 21, 2017), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 14/935,121 (U.S. Pat. No. 9,320,632), filed Nov. 6, 2015 (Apr. 26, 2016), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/133,158 (U.S. Pat. No. 9,584,777), filed Apr. 19, 2016 (Feb. 28, 2017), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/011,321 (U.S. Pat. No. 9,456,914), filed Jan. 29, 2016 (Oct. 4, 2016), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/134,315 (U.S. Pat. No. 9,585,782), filed Apr. 20, 2016 (Mar. 7, 2017), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/415,167, filed Jan. 25, 2017, Delivery Device and Method of Delivery. |
| U.S. Appl. No. 14/656,462 (U.S. Pat. No. 9,375,336), filed Mar. 12, 2015 (Jun. 28, 2016), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 14/935,154 (U.S. Pat. No. 9,445,929), filed Nov. 6, 2015 (Sep. 20, 2016), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/194,410, filed Jun. 27, 2016, Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/000,437 (U.S. Pat. No. 9,433,520), filed Jan. 19, 2016 (Sep. 6, 2016), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/227,757 (U.S. Pat. No. 10,245,167), filed Aug. 3, 2016 (Apr. 2, 2019), Delivery Device and Method of Delivery. |
| U.S. Appl. No. 16/372,224, filed Apr. 1, 2019, Delivery Device and Method of Delivery. |
| U.S. Appl. No. 16/067,082, filed Jun. 28, 2018, Delivery Device and Method of Delivery. |
| U.S. Appl. No. 15/705,793, filed Sep. 15, 2017, Delivery Device and Method of Delivery. |
| U.S. Appl. No. 16/632,841, filed Jan. 21, 2020, Delivery Device and Method of Delivery. |
| Number | Date | Country | |
|---|---|---|---|
| 20170296366 A1 | Oct 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15170772 | Jun 2016 | US |
| Child | 15640095 | US | |
| Parent | 13153257 | Jun 2011 | US |
| Child | 15170772 | US |
